

CURRICULUM VITAE

STEVEN A. KAPLAN, M.D.

Office Address: Department of Urology
Weill Cornell Medical College
F9 West, Box 261
1300 York Avenue
New York, NY 10021
T: (212) 746 - 4811
F: (212) 746 - 5329
E – mail: kaplans@med.cornell.edu

EDUCATION

College: CUNY - Brooklyn College
1974-1978
Brooklyn, New York
BS - Biochemistry

Medical School: Mount Sinai School of Medicine
1978-1982
New York, New York
M.D.

POST GRADUATE TRAINING

Intern: Department of Surgery
1982-1983
Mount Sinai Hospital
New York, New York

Resident: Department of Surgery
1983-1984
Mount Sinai Hospital
New York, New York

Resident: Department of Urology
1984-1988
Squier Urologic Clinic
Columbia-Presbyterian Medical Center
New York, New York

AUA Scholar: Neurourology and Urodynamics
1988 – 1990
Department of Urology
College of Physicians & Surgeons
Columbia University

FACULTY APPOINTMENTS

1988-1989	Instructor Department of Urology College of Physicians and Surgeons Columbia-Presbyterian Medical Center
1990 - 1994	Assistant Professor Department of Urology College of Physicians and Surgeons Columbia-Presbyterian Medical Center
1994 - 1995	Herbert Irving Assistant Professor of Urology College of Physicians & Surgeons Columbia University
1995 - 1997	Herbert Irving Associate Professor of Urology College of Physicians & Surgeons Columbia University
1996-	Vice Chairman Department of Urology College of Physicians & Surgeons Columbia University
1997-1998	Professor of Urology College of Physicians & Surgeons Columbia University
1998 - 2005	Given Foundation Professor of Urology College of Physicians & Surgeons Columbia University
1998 - 2003	Administrator Department of Urology College of Physicians & Surgeons Columbia University
2001 - 2005	Adjunct Professor of Urology Weill Medical College Cornell University
2005 -	Professor of Urology Weill Cornell Medical College Cornell University

HOSPITAL APPOINTMENTS

1988- 89 Assistant Urologist, Department of Urology
Columbia-Presbyterian Medical Center

1990 - 95 Assistant Attending, Department of Urology
Columbia-Presbyterian Medical Center

1990 - Attending, Department of Urology
Helen Hayes Hospital
West Haverstraw, New York

1990 - Director, Prostate Center
Squier Urologic Clinic
Columbia-Presbyterian Medical Center

1993 - Director of Neurourology
Squier Urologic Clinic
Columbia-Presbyterian Medical Center

1993 - Chief, Urology Service
Helen Hayes Hospital
West Haverstraw, New York

1995 - 1997 Associate Attending, Department of Urology
Columbia-Presbyterian Medical Center

1997 - 2005 Attending, Department of Urology
Columbia - Presbyterian Medical Center

1998 - 2002 Administrator, Department of Urology
New York Presbyterian Hospital

2000 - Adjunct Attending
New York Presbyterian Hospital – Weill Cornell

2001 - 2005 Residency Program Director
Department of Urology
Columbia University Medical Center

2003 - 2005 Co – Director, Center for Bladder and Prostate Health
Columbia University Medical Center

2005 Chief, Institute of Bladder and Prostate Health
Weill Cornell Medical College

2005 Attending, New York Presbyterian Hospital
Weill Cornell Medical College

LICENSURES AND FELLOWSHIPS

New York State 1983 # 155937 – 1
American Foundation Urologic Disease Scholar - 1990
Diplomate - American Board of Urology 1992, 2000
Fellow of the American College of Surgeons – 1994

COMMITTEES AND APPOINTMENTS

1988-1994 Chairman, Patient Care Committee
The Presbyterian Hospital

1989-1990 Infection Disease Committee
Helen Hayes Hospital

1989 - 1993 Chairman, Quality Assurance
Department of Urology
Columbia-Presbyterian Medical Center

1989 - 1993 Urology Representative
Continuing Medical Education
Columbia University

1993 - Urology Resident Education Committee

1993 - Faculty Council of Columbia University

1994 - 1996 New York Section American Urologic Association:
Chairman, Young Members Section

1994 American Urologic Association Ad Hoc Committee on
Research

1994 - 1997 American Urologic Association Young Members
Committee

1994 - 2001 Pharmacy & Therapeutics Committee
Columbia - Presbyterian Medical Center

1995 World Health Organization Consultation Panel
on BPH

1996	American Urologic Association BPH Guidelines Committee
1996	American Urologic Association New Technology Committee
1996	American Urologic Association Laser Technology Committee
1996 - 2003	Medicare Compliance Committee Columbia - Presbyterian Medical Center
1996 - 2003	Director Medicare Compliance Department of Urology Columbia - Presbyterian Medical Center
1996	Ad Hoc Reviewer NIDDK O'Brien Grant Committee
1997	Program Committee, American Urologic Association Annual Meeting
2000 - present	Executive Committee, New York Academy of Medicine
2000 - present	Finance Committee, Columbia University Practice Plan
2000 – present	Program Leader: BPH, American Urologic Association Annual Meeting
2001 - present	Executive Committee, Society of Practitioners
2001	Strategic Planning Committee, Columbia University
2002 - present	AUA Education Council
2003	Chair, NIDDK Peer – review, Prostatitis RFA
2003 - present	Columbia University – Practice plan task force
2004 -	Peer review committee: Columbia University FPO
2003 - present	AUA Nominating Committee
2004 -	American Foundation of Urologic Disease: Prostate Council

EDITORIAL RESPONSIBILITIES

Urology (Editorial Board)

Journal of Urology

Journal of Endourology

Urology: Index & Reviews (**Editorial Board**)

Grand Rounds Urology (**Editorial Board**)

Current Urology Reports (**Editor - in - Chief**)

Current Prostate Reports (**Editor – in – Chief**)

Journal of Urology (**Editorial Board**)

British Journal of Medicine (**Editorial Board**)

British Journal of Urology (**Editorial Board**)

European Journal of Urology

Prescriber's Letter / Pharmacist's Letter Specialty Consultants Panel

Medical Review (**Editorial Board**)

BOOKS

- Benign Prostatic Hyperplasia: Laser and Heat Therapy. Eds: Paul Miller, Ian Eardley, Steven Kaplan. Martin Dunitz LTD, 2001
- Minimally Invasive Treatments in Urology Eds: Steven Kaplan, Alan Partin, Anthony Atala, 2005
- Atlas of the Urologic Clinics of North America. Eds: Mark A. Cabelin and Steven Kaplan, 2003

RESEARCH EXPERIENCE

1983-	Transplant Resident Mount Sinai Hospital "Renal and small bowel allografts in the rat"
1986-	Flow cytometry Columbia University "Study of urologic oncology using flow cytometry"
1988-90	Neurourology Columbia University "Parameters of detrusor contractility in an in-vitro whole bladder model in the rabbit"
1990 - 1993	Neurourology Columbia University Neurotrophin expression in diabetic and obstructed bladders"
1991- 1994	Neurourology Columbia University "Gene expression in obstructed rabbit/rat bladders"
1993 - 1996	Neurourology Columbia University "Gene product expression in spinal cord injured rat bladders"
1995 - 1997	Neurourology Columbia University "Alpha adrenergic expression in obstructed rat bladders"
1997 – present	Molecular biology Columbia University "Vascular growth factors in the bladder and prostate"

AWARDS

New York State Regents Scholarship - 1974
New York City Science Honors Program - 1974-1978
Dean's list (CUNY - Brooklyn College) - 1974-1978
Dean's Scholarship Prize- 1978
Summa Caum Laude - 1978
AOA - Mount Sinai School of Medicine - 1981,1982
Arthur Aufses Sr. Surgical Prize - 1982
Ralph Colp Prize for Surgical Journalism - 1986
AUA Essay Contest, 2nd prize in clinical investigation - 1987, 1991
American Federation of Urologic Disease Scholar-1988,1989
Herbert Irving Fellowship - 1994-1997
AUA - EUA Travel Fellowship - 1st alternate - 1996
1st Prize Presentation at NY Section (AUA) Meeting - 1996
Saul Horowitz, Jr. Memorial Award – 1998
John K. Lattimer Urology Lifetime Award – Kidney and Urology Foundation 2003

PROFESSIONAL SOCIETIES

American Medical Association
Diplomate of the National Board of Medical
Examiners - 1983
Urodynamics Society
Westchester Medical Society
New York State Medical Society
American Diabetes Association
National Kidney Foundation
International Continence Society
American Board of Urology
American Urologic Association
American Urologic Association/New York Section
American Association of Clinical Urologists
New York Academy of Medicine
Society of University Urologists
Society for Basic Urologic Research
Chairman: Young Members Group of the New York
Section of the American Urologic Association
Endourology Society
Societe Urologie Internationale
Fellow of the American College of Surgeons

GRANTS (> \$12,600,000)

American Foundation of Urologic Disease Scholar 1988 – 89 (\$50,000)

Paralyzed Veterans of America 1988-1989 (\$27,550)

"Parameters of Detrusor Contractility"

Merck, Sharp and Dohme 1989-1990 (\$118,000)

"Urodynamic parameters in patients on a 5-alpha reductase inhibitor (MK-906)"

Pfizer 1990 (\$67,000)

"The effect of doxazosin on mild hypertension and BPH"

Miles 1990 (\$36,500)

"Low dose, short course therapy using ciprofloxacin in uncomplicated UTI"

Advanced Surgical Intervention, Inc. 1990-91

"Prostatic stents in BPH" (\$10,000)

Berlex, Inc. 1990 (\$57,000)

"Atamestane in Patients with BPH"

Berlex, Inc. 1990 (\$14,500)

"Long Term Usage of Atamestane in Patients with BPH"

Tecnomatix, Inc. 1990

"Transrectal thermal therapy in the management of men with mild to moderate symptoms of prostatism"

American Medical Systems, Inc. 1991 (\$14,000)

"The use of the Wallstent in the management of BPH"

Merck Sharp and Dhome, 1992 (\$134,000)

"Long Term Usage of Proscar in the Treatment of BPH"

Smith Kline Beecham, 1992 (\$145,560)

"A Comparison of Three Dose Levels of SK&F 105657 versus Placebo in the Treatment of BPH"

Abbott Laboratories 1992 (\$77,000)

"Evaluation of the Clinical Effectiveness and Cost Effectiveness of Terazosin vs. Placebo in the Treatment of Patients with Symptomatic Benign Prostatic Hyperplasia"

NIH Grant RU01 DK 46418-01 (\$2,750,012) 9/92 – 10/97

"Drug Therapy for BPH: Urodynamic Correlation"

NIH GrantDK44689 (collaborator) (\$1,567, 890)

"Urinary Bladder Function: A Molecular Approach"

Roberts Pharmaceuticals, 1993 (\$24,700)

The effects of midodrine on women with incontinence"

Schwarz Pharma, 1993 (\$29,650)

A Double-Blind, Placebo-Controlled, Randomized, Two-Way Crossover, Multicenter Study Evaluating Levsin-SL in Influencing Volume of Urine Loss in Incontinent Women"

Yamanouchi Pharmaceuticals, 1993 (\$72,000)

"A Second Phase III Multicenter, Placebo-Controlled Study of Two Dosages (0.4 mg qd and 0.8 mg qd) of modified

release YM 617 in Patients with the Signs and symptoms of Benign Prostatic Hyperplasia"

Merck Pharmaceuticals, 1993 (10,000)

"A Double-Blind, Placebo Controlled, Crossover Study of the Effect of Prazosin on Uroflow in Normal Men"

Yamanouchi Pharmaceuticals, 1993 (\$75,000)

"An open label study using either 0.4 or 0.8 mg of tamsulosin in men with benign prostatic hyperplasia"

SmithKline Beecham Pharmaceuticals, 1994 (\$68,500)

"A two-year, open-label, multicenter study of oral epristeride 80mg once daily in the treatment of benign prostatic hyperplasia"

Abbott Laboratories, 1994 (\$112,350)

"The long term safety and efficacy of terazosin administered once daily for the treatment of symptomatic benign prostatic hyperplasia: an extension of study M91-639R"

Pfizer Pharmaceuticals, 1994 (\$35,000)

"Terazosin versus doxazosin in the management of men with BPH"

Cryomedical Science, 1994 (\$100,000)

"Use of cryosurgery in BPH"

NIH Grant 1995 (\$2,211,000)

2 UO1 DK46418 - 04

"Medical therapy for BPH: A 6 year study"

SmithKline Beecham, 1995 (\$83,000)

"A 1 year study on the efficacy and safety of epristeride in the management of men with benign prostatic hyperplasia"

Pfizer Research Laboratories, 1996 (\$47,431)

"Alpha receptor subtype expression in a rat hypertrophy /hyperplasia model"

ACMI, 1996 (\$25,000)

"Electrovaporization of the prostate in men with benign prostatic hyperplasia"

Urologix, Inc., 1996 (\$40,000)

"Thermotherapy versus TURP in the management of bladder outlet obstruction"

ACMI, 1996 (\$25,000)

"Vaporization versus TURP in the management of BPH"

Medtronic, 1997 (\$50,000)

"Bladder pacemakers"

Synthelabo, 1997 (\$47,500)

"Use of alfuzosin SR in BPH"

DICE Award, 1998 (\$15,000)

"Concomitant doxazosin and Caverjet in patients with erectile dysfunction"

Merck (\$75,000)

"Transition zone measurements in Asian men"

Boehringer Ingelheim, 1998 (\$137, 500)

"Tamsulosin versus terazosin for BPH"

Pharmacia / Upjohn 1999 (\$56,000)

"Long acting Detrol for stress incontinence"

Pharmacia / Upjohn 1999 (\$87,000)

"Detrol in men with BPH and detrusor instability"

Merck (\$47,500) 1999

"Effect of an M-3 inhibitor in the treatment of urge incontinence"

Forrest Pharmaceuticals (\$31,500) 2000
"Effect of LS - 4321 in urge incontinence"

Merck (\$27,500) 2000
"Vioxx in the management of chronic prostatitis"

Wellspring (\$64,000) 2001
"The effect of dibenzylamine in men with BPH"

NIH Grant (DK608004 – 01) 2001 (\$2,350,000)

DK4641: P.I.

"Minimally invasive alternative therapies: Multiethnic and urodynamic variability"

NIH Grant (DK) 2002 (\$2,145,678): P.I.

" Phytotherapeutic agents in men with BPH"

Pharmacia (\$43,550) 2002
"Detrol in men with urgency"

Pfizer (67,845) 2004
"Use of sertraline in patients with interstitial cystitis"

PRESENTATIONS

New York Surgical Society, December , 1984, New York, NY
"Small Bowel Transplantation in the Rat"

Ferdinand Valentine Essay Contest, April, 1985, New York, NY
"Prostate Cancer in Men Under the Age of 45"

Ferdinand Valentine Essay Contest, April 1986, New York, NY
"Contemporary Cystectomy Versus Preoperative Radiotherapy and Cystectomy for Invasive Bladder Cancer"

AUA Annual Meeting, May, 1986, New York, NY
"Contemporary Cystectomy Versus Preoperative Radiotherapy and Cystectomy for Invasive Bladder Cancer"

AUA Annual Meeting, May, 1987, Anaheim, CA
"Flow Cytometric Identification of Subtle Degrees of Tumor Aneuploidy Using a New DNA Index"

International Society of Analytical Cytology, August 1987 (Cambridge University, Great Britain)

"The Use of Mean Channel Number Versus Modal Channel Number in Flow Cytometric Analysis"

Winner Chief Residents Debate, February, 1988

New York Academy of Medicine

AUA Annual Meeting, June, 1988, Boston, MA

"Urine Versus Bladder Barbotage in the Flow Cytometric Diagnosis of Bladder Cancer"

"Urodynamic Findings in Spinal Cord Injury and Myelodysplasia"

Urodynamics Society, May, 1989, Dallas, TX

"Parameters of Detrusor Contractility in an In-Vitro Whole Rabbit Model"

AUA Annual Meeting, May, 1989, Dallas, TX

"Hypospadias: Behavior and Gender Role Development"

Marquette General Hospital, May, 1989, Marquette, WI

"Update in the Management of Prostate Cancer"

Allen Pavilion, May, 1989, New York, NY

"Alternative Management of BPH"

New York Academy of Medicine, May, 1989, New York, NY

"Fellow's Night"

"Parameters of Detrusor Contractility in an In-Vitro Rabbit Whole Bladder Model"

Eisenhower Medical Center, July, 1989, Augusta, GA

"Alternative Management of BPH"

International Continence Society, September, 1989, Ljubljana, Yugoslavia

"Parameters of detrusor contractility: The Effect of Outlet Resistance on Work, Power and Qmax in an In-Vitro Rabbit Whole Bladder Model"

American College of Surgeons, October, 1989, Atlanta, GA

"The Effect of Volume and Hysteresis on Work, Power and Wf"

International Center for the Disabled, January, 1990, New York, NY

"Management of Urinary Incontinence"

Kettering Hospital, February, 1990, Kettering, OH

"Medical Management of BPH"

Visiting Professor, University of Tennessee at Memphis, April, 1990

"New Ways to Treat BPH"

AUA Annual Meeting, May, 1990, New Orleans, LA

"Parameters of Detrusor Contractility II: The Effect of Outlet Resistance on Work, Power and WF"

"Bladder and Sphincter Behavior in Patients with Spinal Cord Injury"

St. Luke's Hospital, July, 1990, New York, NY

"Management of Incontinence"

Roosevelt Hospital, August, 1990, New York, NY

"Female Stress Incontinence"

Tri-City Urology Society, September, 1990, Tri-City, NC

"Non-Surgical Management of BPH"

Update in Infection Management, October 1990, New York, New York

"Update in Management of Urinary Tract Infection"

American Society of Clinical Hyperthermia, November, 1990, Atlanta, GA

"The Use of Transrectal Hyperthermia in BPH"

Prostatic Disease: A Review Of Current Management, New York, New York November, 1990

"New Concepts in the Management of Prostatitis"

"Update in the Management of Prostate Disease", New York, New York December 8-9, 1990

Course Co-Director

"Alpha-Blockers & 5 alpha-reductase inhibitors in BPH"

"Prostatic Stents"

"Prostate Hyperthermia"

AUA Annual Meeting, June, 1991, Toronto, Canada

Instructional Course

Benign Prostatic Hyperplasia

"Legal Implications of Prostate Treatment" (Symposium)

American Urological Association, 1991

Prostate Stents and Hyperthermia

American Diabetes Association Annual Meeting, June, 1991, Washington, D.C.

"SGP-2 Expression in Diabetic Rat Bladders"

South Florida Urology Association, October 1991, Miami, FL

"The Use of Prostate Stents in the Elderly Population"

AUA, NY Section, October, 1991, Scottsdale, AZ

"Titanium Stents in Geriatric Patients in Urinary Retention"

"Neurotrophin Expression in Diabetic Rat Bladders"

American College of Surgeons, October 1991, Chicago, IL

"Genetic Response of the Rat Bladder During the Onset of Streptozotocin Induced Diabetic Cystopathy"

Society of Minimally Invasive Disease, November, 1991, Boston, MA

"Prostatic Stents in Urinary Retention"

Grand Rounds, New York University, December, 1991, New York, NY

"Non-Medical, Alternative Therapy in BPH"

"Update in the Management of Bladder Disease", December, 1991, New York, NY

Course Co-Director

"Urodynamic Evaluation of Incontinence"

American Urological Course Postgraduate Course on BPH

Washington, December 1991

"Urodynamic Evaluation: Indications and Pitfalls"

"Balloon Dilatation: Pro"

"Hyperthermia: Clinical Results"

3rd International Conference on Geriatric Nephrology and Urology, April 1992, Toronto, Canada

"Balloons, stents and hyperthermia"

AUA, Annual Meeting, May 1992, Washington, D.C.

"Applicator-urethral distance and pre-treatment urodynamics as prognostic indicators"

"Alternative therapy for symptoms of prostatism: What do patients want?"

"The titanium prostatic urethral stent: The United States experience."

Urodynamics Society, May, 1992, Washington, D.C.,

"Prostatic stents in the management of geriatric men with prostatism"

American Hospital, June, 1992, Paris, France

"Alternative Management of BPH"

European Association of Urology, (Xth Congress) July, 1992, Genoa, Italy
"Daytime versus nighttime dosing of the long acting alpha blockers, terazosin and doxazosin"

Astoria General Hospital, September 1992, Astoria, NY
"Advances in Prostate Cancer and BPH"

AUA Instructional Course (BPH), September 1992, Nashville, TN
"Balloon dilation of the prostate"
"Transrectal hyperthermia"

Pittsburgh Urological Society, September 1992, Pittsburgh, PA
"Update in the Management of BPH"

Nebraska Urologic Society, September 1992, Lincoln, NE
"Use of alpha blockers in the management of BPH"

Lenox Hill Hospital Symposium, September, 1992, New York, NY
"Alternate management of BPH"
"Use of prostatic stents"

AUA, NY Section, October, 1992, Berlin, Germany
"Periurethral Fat/Collagen in Type III Stress Incontinence"
"Coils/Hyperthermia in BPH"

Technological Advances in Adult and Pediatric Urology, December, 1992 (Course Co-Director)
"Prostatic Urethral Stents"
"TULIP/VLAP"

Maimonedes Hospital (Grand Rounds), January, 1993, Brooklyn, NY
"Management of Incontinence"
"Alternative Management of BPH"

New York Academy of Medicine, January, 1993, New York, NY
"Technological Advances in BPH"

Bronx VA Hospital Grand Rounds, January, 1993, Bronx, NY
"Medical Management of BPH"

Mount Sinai Grand Rounds, February, 1993, New York, NY
"Diagnosis and Treatment of BPH"

Visiting Professor, University of Southwest Florida, February, 1993, Tampa, FL
"Update in the Management of BPH"

Brookdale Hospital Grand Rounds, March, 1993, Brooklyn, NY

"Alternative Treatment of BPH"

Puerto Rican Urological Association, March, 1993, Ponce, PR

"Economic impact of prostate disease"

"Non-medical alternatives for BPH"

Clinical Society of Genitourinary Surgeons, March, 1993, New York, NY

"Novel molecular approaches in bladder dysfunction"

New York Section Seminar, March, 1993, New York, NY

"Surgical treatment of BPH"

Nebraska Urologic Society, April, 1993, Omaha, NE

"Update in finasteride therapy"

"Hyperthermia in BPH"

AUA, Annual Meeting, May 1993, San Antonio, TX

Urodynamics Society

"Efficacy and safety of the long acting α_1 - agonist, doxazosin in patients with BPH"

BPH Showcase

"Prostate stents and hyperthermia"

AUA Instructional Course (Course Director)

"BPH"

"Use of the TITAN intraprostatic stent in men with BPH: preliminary results from the United States National Cooperative Study".

"Comparison of gene expression in streptozotocin induced diabetic cystopathy and osmotic diuresis in rat bladders"

"Regression of the hypertrophied rabbit bladder after release of outlet obstruction involves extensive apoptosis of specific cellular elements."

"Urodynamic evidence of vesical neck obstruction in men with chronic prostatitis and the therapeutic role of TUIP"

"Patient demographics as prognostic variables for choice of treatment in prostatism.

Bronx Lebanon Grand Rounds, June, 1993, Bronx, NY

"Update in the management of BPH"

Video Urology, 3rd Congress, June, 1993, Orlando, FL

"Drug therapy for BPH"

Mediterranean Urology Association, July, 1993, Istanbul, Turkey

"5 alpha-reductase inhibitors for BPH"

Visiting Professor, Cyprus Medical Society, July, 1993, Nicosia
"Alternative therapy in BPH"

Jewish Home for the Aged, July, 1993, Bronx, NY
"Management strategies for BPH in the elderly population"

Miami Urological Association, August, 1993, Miami, FL
"Medical management for BPH"

West Point Grand Rounds, September, 1993, West Point, NY
"Update in the management of BPH"

St. Joseph Hospital, September, 1993, Queens, NY
"Alpha blockade in the management of hypertension and BPH"

Mather Memorial Hospital, September, 1993, Port Jefferson, NY
"Medical management for BPH"

St. Vincent Hospital, October, 1993, Staten Island, NY
"Internal Medicine Update: Management of BPH"

St. Barnabas Hospital, October, 1993, Bronx, NY
"What's new in Urology?"

Booth Memorial Hospital, November, 1993, Flushing, NY
"Natural history of BPH"

American Academy of Family Physicians, November, 1993, Huntington, West Virginia
"Pharmacology of BPH"

Western Section, American Urologic Association, November, 1993, Palm Springs, California
"New Trends in Urology" (Program Chairman)
"Medical Management of BPH"

Lenox Hill Hospital, December, 1993, New York, NY
"Prostatic urethral stents"

St. Francis Medical Center, January, 1994, Pittsburgh, PA
"Alternative therapy for BPH"

Stony Brook Medical Center, January, 1994, Stony Brook, NY
"Medical Management of BPH"

Annual Review of Internal Medicine, Northwestern Medical Center, Chicago, Illinois, January, 1994

"New Therapeutic Trends in Urology"

Jacksonville Urological Association, Jacksonville, FL, March, 1994

"Medical management of BPH"

4th International Conference on Prostate and Urothelial Cancer Benign Prostatic Hyperplasia, Orlando, FL, March 1994

"Future trends in BPH"

1st Annual International Symposium of the Institute of Urology and Transplantation, Karachi, Pakistan, March, 1994

"Future trends in the management of BPH"

"Finasteride in the treatment of BPH"

AUA, Annual Meeting, San Francisco, CA, May, 1994

BPH Seminar

"Pressure/Flow evaluation of men with BPH"

"Thermotherapy in the management of BPH"

AUA Instructional Course (Course Director)

"BPH"

"Urodynamics and the etiology of post-prostatectomy incontinence"

"Androgen deprivation and apoptosis in rat erectile tissue"

"Use of the AUA-BPH treatment guidelines in men with symptomatic benign prostatic hyperplasia (BPH): at one year does it work?"

St. Joseph's Medical Center, Denver CO, June, 1994

"Medical therapy of BPH"

Grand Rounds, New York Medical College, June, 1994

"BPH Guidelines"

Spring Meeting of the New York Section of the American Urologic Association, Rye, NY, June, 1994

Program Chairman

"Update on Prostatitis"

Florida Urological Association, Miami, FL, September, 1994

"Alpha Blockade and Finasteride Use in Men with BPH"

New York Section American Urologic Association, London, UK, October, 1994

"The Use of the AUA Symptom Score"

3rd International Conference on Parkinson's Disease, New York, NY, October, 1994

"Urologic Dysfunction in Patients with Parkinson's Disease"

AUA Urologic Instructional Course on BPH, Houston, TX, October, 1994

"Epidemiology of BPH"

"Uroflow Evaluation"

"Balloon Dilatation: Is it an Option"

"Prostatic Urethral Stents"

The Great Prostate Debate, New York, NY, November, 1994

" Program Moderator"

Perspectives in Urology, Phoenix, AZ, December, 1994

"Future Trends in Urology"

Visiting Professor, Universidade de Sao Paulo, Brazil, February, 1995

"Molecular staging of prostate cancer"

"New advances in the treatment of incontinence"

"Electrovaporization of the prostate"

AUA Annual Meeting, Las Vegas, NV, April, 1995

World Health Organization Surgical Subcommittee Meeting:

"Transurethral electrovaporization of the prostate"

"A new voiding classification system for evaluation of young men with voiding dysfunction based on urodynamic findings"

"Transurethral electrovaporization of the prostate (TVP), a novel method for treating men with benign prostatic hyperplasia: comparison to laser TURP"

"Transurethral electrovaporization of the prostate (TEVAP)" (video)

BPH: Options for Care (Evening Seminar)

(Program Chairman)

" Minimally invasive alternative treatment for BPH"

3rd International Conference on BPH, Monte Carlo, June 1995

"Electrovaporization of the Prostate"

"Alpha blockade: monotherapy for hypertension and BPH"

"Doxazosin does not adversely affect blood pressure of physiologically or pharmacologically normotensive patients with benign prostatic hyperplasia"

"Doxazosin in elderly men with BPH"

Italian Urological Society, Rome, July, 1995

“Medical management of BPH”

Medical Grand Rounds, St. Peter’s Hospital, New Jersey, August, 1995

“New treatment strategies for BPH”

New York Section (American Urological Association), Istanbul, Turkey, October, 1995

“Lasers in the management of BPH”

“New surgical trends in BPH”

Grand Rounds, Winthrop Hospital, Mineola, NY October, 1995

“What’s new in BPH?”

Visiting Professor, Hahneman University, Philadelphia, PA, November, 1995

“Prostate Management in 1995”

AUA Instructional Course, “The Prostate”, Atlanta, GA, November, 1995

“Pressure / Flow Studies in BPH”

“Alpha Blockade in BPH”

“Electrovaporization and TUNA”

“Prostate Stents”

“Cryotherapy for Prostate Cancer”

XX Brazilian Congress of Urology, Salvador, Bahia, November, 1995

“Finasteride in the management of BPH”

“Alpha Blockers in BPH”

“Electrovaporization of the Prostate”

“Management of stress urinary incontinence”

“The future of BPH”_

Grand Rounds, Beth Israel Medical Center, New York, NY January, 1996

“Medical management of BPH?”

Grand Rounds, Maimonedes Hospital, Brooklyn, NY January, 1996

“Electrovaporization in BPH”

Grand Rounds, University of California (Irvine), March, 1996

“Therapeutic trends in BPH”

Argentinan Urology Conference, Buenos Aires, April, 1996

“Role of sympathetic tone in the modulation of bladder outlet obstruction”

American Urological Association Annual Meeting, Orlando, FL, May, 1996

Urodynamics Society

"New Surgical Alternatives for BPH - Results"

"Electrovaporization of the prostate for symptomatic benign prostatic hyperplasia: the 1 year experience"

Urodynamics Society Forum

"Results of non - pharmacologic therapy for BPH"

Program Chairman: "BPH - Where are we in 1996?"

"Minimally invasive alternative therapy for BPH" Plenary Session - Debate Moderator

"The place of urodynamics in the evaluation of the patient with BPH"

Plenary Session

" The role of the Vaportrode in BPH"

Urotrend 2000 June, 1996, Hamilton, Bermuda

Program Chairman

"Minimally invasive therapy for BPH"

"Phytotherapy for BPH"

Update in Internal Medicine (Colulumbia University / Harvard Medical School) August 1996

"Review of Prostate Disease"

Grand Rounds, Hackensack Hospital, September, 1996

"BPH Management"

Grand Rounds, JFK Rehabilitation Hospital, September, 1996

"Management of the neurogenic bladder"

Urotrend 2000, Monte Carlo, Monaco, October, 1996

Program Co - Chairman

"BPH: Where are we in 1996?"

AUA (NY Section), Paris, France, October, 1996

Program Co - Chairman

"Electrovaporization of the prostate"

Incontinence panel: moderator

Puerto Rican Urology Association, Annual Meeting, San Juan, November, 1996

“Cryotherapy for prostate cancer”

“Sling procedures for incontinence”

“Medical therapy for BPH”

Urotrend 2000 December, 1996, Boca Raton, Florida

Program Chairman

“Minimally invasive therapy for BPH”

“Phytotherapy for BPH”

“Non - surgical management of urinary incontinence”

3rd Urology Board Review Course, December, 1996, Chicago, IL.

“Neurogenic bladder”

“Female urology”

Philadelphia Urology Association, January, 1997

“Electrovaporization of the prostate”

Memorial Hospital Urology Update, February, 1997

“Vaginal wall sling for stress urinary incontinence”

European Institute of Urology Symposium, Milan, Italy, February, 1997

“Alpha blockade for lower urinary tract symptoms”

Challenging Cases in Urology, Miami, Florida, February, 1997

“BPH”

American Urological Association Annual Meeting, New Orleans, April, 1997

“Electrovaporization of the prostate: an overview”

“Alpha Blockade in the next century”

“Analysis of patient satisfaction with treatment for benign prostatic hyperplasia (BPH) based on race”

American Geriatric Society, Atlanta, May, 1997

“The role of medical therapy in treating geriatric men with BPH”

British Urology Association, Bournemouth, United Kingdom, June, 1997

“BPH: the next millenium”

4th Annual BPH Consultation, World Health Organization, Paris, July, 1997

“Patient satisfaction with BPH therapy”

“Alpha blockade and sexual therapy”

“Electrovaporization”

Societe Urologie Internationale, Montreal, September, 1997

"Improved sexual function utilizing alpha blockade"

Grand Rounds, Beth Israel Medical Center, November, 1997

"BPH: The next millennium"

XXI Brazilian Urology Congress, November, 1997

"Molecular biology of prostate cancer"

"Vaporization of the prostate"

Visiting Professor, SUNY – Downstate Medical Center, January, 1998

"Medical therapy for BPH: symptoms versus progression"

European Institute of Oncology – Milan, Italy, February, 1998

"RT – PCR PSA for detecting prostate cancer"

Annual Meeting European Urology Association, Barcelona, March, 1998

"Electrovaporization of the prostate": pros and cons

"Symptom response during the PLESS study" _

China Urology Association, Shanghai and Beijing, May, 1998

"Does new treatment for BPH mean better treatment?"

American Urological Association Annual Meeting, San Diego, June, 1998

"BPH: Highlights"

"Alpha Blockade in the next century"

"Baseline symptom severity and its relationship to long – term response to finasteride".

"Medical therapy of prostate symptoms (MTOPS): baseline urodynamic data and correlation with prostate volume and prostate specific antigen (PSA)"

Dutch Urological Association, Amsterdam, July, 1998

"Can medical therapy for BPH alter the progression of disease?" _

New York Section, American Urological Association, Prague, October, 1998

"Diagnosis of stress urinary incontinence"

"Results of PLESS: analysis based on baseline serum prostate specific antigen"

"Minimally invasive alternative therapy for BPH"

Visiting Professor, Robert Wood Johnson Medical School, December, 1998

"Management of BPH in 1998"

Visiting Professor, University of Illinois, March, 1999

"Basic science concepts in BPH"

American Urological Association Annual Meeting, Dallas, May 1999

"Medical therapy of BPH"

"Dual placement of an artificial urinary sphincter (AUS) and a Urolume Wallstent for male sphincteric incontinence (SUI) and recurrent bladder neck contracture"

"Effect of finasteride on filling and voiding symptoms of BPH"

"Electrovaporization of the prostate utilizing the roller ball and / or vaporizing loop for symptomatic benign prostatic hyperplasia (BPH): The 4 – year Columbia experience"

Beijing Society of Urology, August, 1999

"Does progression of BPH matter?"

"Transition zone index in Asians"

Korean Urology Association, August, 1999

"Prostate reduction in Asian men"

American College of Surgeons, October, 1999

"BPH: The Next Millennium"

New York Section, AUA, Dublin, October, 1999

"BPH: United States Perspective"

"Transition zone index in Asians"

Toronto Urological Association, Toronto, November, 1999

"Medical Management of BPH"

"Minimally invasive treatments for BPH"

5th National Urology Board Review, Chicago, December, 1999

"Neurophysiology of Voiding"

"Management of Stress Incontinence"

Winter Urologic Forum, Telluride, January, 2000

"BPH – new treatment modalities"

"Stress urinary incontinence – surgery"

"Female sexual dysfunction"

Annual Meeting of the American Urological Association Meeting, Atlanta, 2000

“The role of 5 – alpha reductase inhibitors in the management of BPH (AUA Plenary Course)

Plenary presentation: “BPH highlights”

“Depression and female sexual function in women with urinary incontinence”

“Doxazosin for the treatment of concomitant hypertension and benign prostatic hyperplasia (BPH): an open - label study in patients with well controlled hypertension”

“Combined long term results based on initial prostate size of U.S. multi - center studies using the TARGIS system for benign prostatic hyperplasia”

“The efficacy and safety of finasteride in elderly men with benign prostatic hyperplasia”

New York Section, American Urological Association, Capetown, October, 2000

“Progression of BPH” : Myth or Reality?

6th Annual Urology Board Review, Chicago, IL, December 2000

“Stress urinary incontinence”

Grand Rounds, Long Island College Hospital, January, 2001

“What’s new in BPH”

Annual AUA Board Review Course, Chicago, IL, March, 2001

“Minimally Invasive Treatments for BPH”

Annual Meeting of the American Urological Association, Anaheim, 2001

Urodynamics Society

“Medical Management of BPH in 2001”

“Update on Alpha Blockers” AUA Post graduate course

“Combined long term outcomes stratified by patients age at treatment. Results of the Targis system multi – center study for benign prostatic hyperplasia (BPH)”

“BPH: Take home message”

Visiting Professor, Rome University, Rome, Italy, 2001

“What’s New in BPH?”

Grand Rounds, Lenox Hill Hospital, September, 2001

“Minimally invasive alternative therapies for BPH”

Long Island Surgical Society, December, 2001

“Minimally invasive alternative therapies for BPH”

7th Annual Urology Board Review, Chicago, IL, December 2001

“Urodynamics and neurogenic bladder”

“Stress urinary incontinence”

Winter Urologic Forum, Telluride, Co, February 2002

“Pathophysiology of BPH”

“Medical therapy for BPH”

“Adjuvant therapy for prostate cancer”

Annual AUA Review Course, Chicago, IL, March, 2002

“Minimally invasive therapies for BPH”

Taiwan Urology Forum, Taipei, April, 2002

“Medical therapy for BPH”

Annual Japanese Urology Association Meeting, Tokyo, April, 2002

“Update on the treatment for stress urinary incontinence”

“Medical therapy for BPH”

Society of Urodynamics and Female Urology, Orlando, May, 2002

“Disappointing results with bone anchors for stress urinary incontinence”

American Urological Association Annual Meeting, Orlando, May, 2002

“Pharmacologic management of BPH”

“Disappointing long term results of transvaginal bone anchors in the treatment of stress urinary incontinence (SUI): The 3 – year New York Presbyterian Hospital experience”

“Use of finasteride as a diagnostic tool in evaluating men with a serum PSA > 4 and previous negative prostate biopsy”

“Urodynamic findings in men with DM and BPH”

“Long term efficacy and durability in 345 patients treated with transurethral microwave thermotherapy for benign prostatic hyperplasia: Five year results”

“Electrovaporization of the prostate utilizing the roller ball and / or vaporizing loop for symptomatic benign prostatic hyperplasia (BPH): The 7 – year Columbia experience in 650 consecutive men”

“Pressure / Flow evaluation of ethnically diverse men treated by minimally invasive surgical therapies for BPH: The New York Presbyterian Hospital experience”

UMDNJ, Rutgers Medical School, September , 2002

Visiting Professor

“Minimally invasive therapies for BPH”

American Urologic Association Meeting, New York Section, Barcelona, Madrid, October, 2002 SCIENTIFIC CHAIRMAN

“Results of MTOPS”

“Sexual function and BPH”

State University, Downstate Medical School, November, 2002

Visiting Professor

“Results of MTOPS”new algorithms for medical therapy”

American Urologic Association, Post Graduate Course, Keystone, Colorado, January, 2003 Course Director

“Pathophysiology of BPH”

“Alpha Blockers for BPH”

“5α – reductase inhibitors”

“Minimally invasive therapies for BPH”

UCLA, State of the Art Conference, Marina del Rey, February, 2003

“BPH management in 2003”

Chicago Urology Association, Annual Meeting, March, 2003

“Medical therapy for BPH”

1st Annual Nagamatsu lecture, New York, March, 2003

“New technologies in BPH”

American Urologic Association Annual Meeting, Chicago, April, 2003

“BPH: 2003, trends for the future”

“State – of – the – Art: Medical Therapy for BPH”

“Illicit ketamine abuse (special K) causing eosinophilic cystitis”

“Baseline measures predict the risk of benign prostatic hyperplasia clinical progression

in placebo – treated patients”

“Baseline symptoms, uroflow, and post void residual urine as predictors of BPH clinical progression in the medically treated arms of MTOPS”

“Impact of baseline symptom severity on general health and sexual satisfaction in men with BPH treated with finasteride or placebo”

“High power KTP photoselective laser vaporization prostatectomy for the treatment of benign prostatic hyperplasia in men with large prostates”

“Long term safety and efficacy in 147 patients treated with prostate stents for benign prostatic hyperplasia(BPH):12 – year results”

“Serum prostate specific antigen levels following transurethral microwave thermotherapy”

Hackensack University Medical Center, May, 2003

“MTOPS and their impact on the treatment of BPH”

Spanish Urology Association, Gran Canaria, May, 2003

“Medical therapy of BPH – MTOPS”

“Chronic prostatitis – current trends in management”

Visiting Professor, University of Tennessee, October, 2003

“PCPT and MTOPS: Impact on Urology”

“Minimally invasive therapies for BPH”

University of Toronto, Visiting Professor, November, 2003

“New paradigms in the treatment of BPH”

French Urological Association, November, 2003

“Impact of MTOPS on treatment of BPH”

European Association of Urology, March, 2004

“Sexual dysfunction and BPH”

American Urologic Association Annual Meeting, San Francisco, May, 2004

“BPH: 2004

“Sexual function in ethnically diverse men Category III prostatitis / chronic pelvic pain syndrome”

“Chromosome 13 syndrome: A pleiotropic genetic linkage between panic disorder and interstitial cystitis”

“Impact of baseline symptom severity on threshold changes to trigger crossing over to active therapy in the MTOPS trial”

“Impact of baseline PSA and TRUS volume on longitudinal changes in IPSS and maximum flow rate in MTOPS”

“Use of muscarinic receptor antagonists as monotherapy in men with lower urinary tract symptoms who failed previous therapy with alpha blockers”

“Dutasteride provides improvement in urodynamic parameters over 2 years: analysis of data from the Phase III dutasteride studies”

“High – power KTP photoselective laser vaporization prostatectomy in men with large prostates: The New York Presbyterian series of 64 patients”

“High – power KTP photoselective laser vaporization prostatectomy (PVP) versus transurethral electrovaporization of the prostate (TVP) for the treatment of benign prostatic hyperplasia (BPH): a prospective comparative trial”

Grand Rounds, Department of Urology, Washington University, July, 2004

“Progression of symptoms and BPH”

Visiting Professor, Department of Urology, Temple University, October, 2004

“Sex and BPH: Are they related?”

“Muscarinic receptor antagonists in men with BPH”

“Update on the AUA Guidelines for BPH”

Society of Female Urology and Urodynamics, Orlando, February, 2005

“BPH: MIST Trials”

European Association of Urology, Istanbul, March, 2005

“Sexual dysfunction and BPH”

“Combined use of doxazosin and finasteride in men with prostate size 25 – 40 ml”

American Urologic Association Annual Meeting, San Antonio, May, 2005

“Use of muscarinic receptor antagonists in men with BPH and LUTS”

“The role of 5 α – reductase inhibitors in men with BPH”

Franco – American Society Meeting

“BPH”

Society of Female Urology and Urodynamics, Program Chair

“BPH”

Course Director

“BPH 2005: New terminology, definitions and treatment paradigms”

State of the Art Lecture

“Lower urinary tract symptoms and sexual dysfunction”

“The superior beneficial effect of combination therapy with doxazosin and finasteride versus either drug alone on clinical progression of benign prostatic hyperplasia is not dependent on patients having prostate enlargement at baseline: data from the medical therapy of prostatic symptoms (MTOPS) trial.

British Association of Urologic Surgeons, Glasgow, June, 2005

“Update on MTOPS”

Visiting Professor, University of California, Irvine, July, 2005

“Overactive bladder in men”

“Musings on MTOPS and PCP”

“Sexual dysfunction and LUTS”

Puerto Rican Urology Association Meeting, San Juan, November, 2005

“Sexual function and BPH”

“Chemoprevention for prostate cancer”

PUBLICATIONS (Total 364)

Peer Reviewed

1. **Kaplan SA**: Double lumen Hickman catheters in long term dialysis. *Kidney International*, 19:47 - 51, 1983.
2. Shanzer H, **Kaplan S**: Double lumen silicone rubber indwelling venous catheters. *Archives of Surgery*, 121, 89-94, 1986.
3. **Kaplan SA**, Shanzer H, Racelli D, et al: Orthotopic, segmental small bowel transplantation in the rat. *Mount Sinai Journal of Medicine*, 53: 112-116, 1986.
4. Benson MC, **Kaplan SA**, Olsson CA: Prostate cancer in men under the age of 45. *Journal of Urology*, 137:888 - 890, 1987.
5. **Kaplan SA**, Karp F, Benson MC: Use of a DNA index and mean channel number to identify subtle degrees of aneuploidy. *Cytometry*, 45:37 - 44, 1987.
6. **Kaplan SA**, Benson MC: Mean channel number versus modal channel number in flow cytometric analysis. *Journal of Urology*, 139: 322 - 327, 1988.
7. **Kaplan SA**, Blaivas JG: A practical approach to the diagnosis of urinary incontinence. *Seminars in Neurology* 53:139-142, 1988
8. Blaivas JG, **Kaplan SA**: Urological dysfunction in patients with multiple sclerosis. *Seminars in Neurology*- 51: 325-230, 1988.
9. **Kaplan SA**, Blaivas JG: Lower urinary tract manifestations in diabetes mellitus. *Journal of Diabetic Complications*. 3:15 - 19, 1988
10. **Kaplan SA**, Sawczuk IS, Olsson CA: Contemporary cystectomy versus preoperative radiotherapy and cystectomy for invasive bladder cancer. *Urology* 38: 67 - 71, 1988.
11. **Kaplan SA**, Brown WC, Blaivas JG: Parameters of detrusor contractility: Effects of hysteresis and bladder volume in an in-vitro whole rabbit model. *Surgical Forum* 40: 665-666, 1989.
12. **Kaplan SA**, Blaivas JG, Brown WC, Schuessler GB: Parameters of detrusor contractility: I: The effect of bladder volume and outlet resistance on Q_{max}, power and work in an in-vitro whole rabbit model. *Neurourology Urodynamics* 8(4):375-376, 1989.

13. **Kaplan SA**, Brown WC, Chancellor MB, Schuessler GB, Blaivas JG: Parameters of detrusor contractility: II: The effect of outlet resistance on the mechanical indices: power, work and Wf. J Urol 143:354 - 357, 1990.
14. **Kaplan SA**, Blaivas JG: Management of bladder problems of the MS patient. Journal of Enterostomal Therapy, 13:16 - 20, 1990.
15. **Kaplan SA**, Brown WC, Levin RM, Blaivas JG: Parameters of detrusor contractility: I: The effect of hysteresis, electrical stimulation and bladder volume in an in-vitro whole rabbit model. Neurourology and Urodynamics. 10:53 - 57, 1991.
16. Chancellor MB, Blaivas JG, **Kaplan SA**, Axelrod S: Bladder outlet obstruction versus impaired detrusor contractility: the role of uroflow. J. Urol, 145:810 - 814, 1991
17. **Kaplan SA**, Chancellor MB, Blaivas JG: Bladder and sphincter behavior in patients with spinal cord injury. J. Urol. 146:113 - 117, 1991.
18. Koo HP, Buttyan R, Olsson CA and **Kaplan SA**: Genetic response of the rat bladder during the onset of streptozotocin induced diabetic cystopathy. Surgical Forum, 42:36 - 41, 1991.
19. **Kaplan SA**, Shabsigh R, Soldo KA and Olsson CA: Prostatic and Periprostatic Interstitial Temperature Measurements During Transrectal Hyperthermia. J Urol, 147:1562 - 1565, 1992.
20. **Kaplan SA**, Kohn I, Amis S, O'Toole K, Bixon R and Giella J: Renal angiomyolipoma presenting as a retroperitoneal hemorrhage after thrombolytic therapy for acute myocardial infarction. N.Y. State J. Med. 92 (5)17 - 20, 1992.
21. Benson MC, Whang IS, Pantuck A, Ring K, **Kaplan SA**, Olsson CA, Cooner WH: Prostatic specific antigen: Means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol, 147(3):815 - 819, 1992.
22. **Kaplan SA**, Benson MC: Arterio-venous malformation of the ureter. Urology, 40(5): 450-2, 1992.
23. Chancellor MB, **Kaplan SA**, Blaivas JG: A new method of measuring uroflow in the rat bladder. Neurourology and Urodynamics. 11:(2) 123 - 129, 1992.
24. **Kaplan SA**, Blaivas JG: Neurophysiology of storage and voiding function. Current Opinion in Urology, 2(4):248-251, 1992.
25. Te AE, Buttyan R, Koo HP, Olsson CA, **Kaplan SA** : Nerve growth factors in diabetic cystopathy Neurourol & Urodynam 11:4:303-304. 1992.

26. Chancellor MB, **Kaplan SA**, Blaivas JG: The cholinergic and purinergic components of detrusor contractility in a whole rabbit bladder model. *J Urol*,148:906-909, 1992
27. Koo HP, Buttyan R, Olsson CA, Shabsigh R and **Kaplan SA**: Early molecular changes associated with streptozotocin-induced diabetic bladder hypertrophy in the rat. *Urol Res* 1993; 21 (6):375-81.
28. **Kaplan SA**, Shabsigh R, Soldo KA, Blaivas JG and Olsson CA: Applicator-urethral distance as a predictor of response after transrectal thermal therapy. *Br. J. Urol* 72 (2): 195-200, 1993.
29. **Kaplan SA**, Soldo KA, Olsson CA: Daytime versus nighttime dosing of the long acting alpha blockers, terazosin and doxazosin. *Urology* 42:129 - 132, 1993.
30. Walton GR, **Kaplan SA** : Urinary dysfunction in tropical spastic paraparesis: preliminary urodynamic survey. *J Urol.* 150 (3): 930-2, 1993.
31. **Kaplan SA**, Merrill DC, Benson RC, Jr, Fuselier HA, Moseley WG, Parra R: The titan intra-prostatic stent: the early United States experience. *J Urol*, November, 150:1198- 201, 1993.
32. Santarosa R, Colombel M, **Kaplan SA**, Monson F, Levin R, Buttyan R: Regression of the hypertrophied rabbit bladder involves extensive apoptosis of cells in the urothelium and serosal lamina. *Laboratory Investigation*, 70:503 - 510, 1994.
33. **Kaplan SA**, Koo HP: Benign prostatic hyperplasia. *Compr Ther* 19(1):21-4, 1993.
34. **Kaplan SA** and Olsson CA: Microwave therapy in the management of men with BPH: current status. *J. Urol* Nov; 150 (5) Pt 2): 1597-602, 1993.S
35. Seaman EK, Jacobs BZ, Blaivas JG, **Kaplan SA** : Persistence or recurrence of symptoms after TURP: A urodynamic assessment. *J. Urol* Sep: 152 (2) 935-7, 1994.
36. **Kaplan SA**, Soldo KA and Olsson CA: Effect of dosing regimen on efficacy and safety of doxazosin in normotensive men with symptomatic prostatism. *Urol Sep* 44(3): 348:52, 1994.
37. Te A, Buttyan R, Greene L, **Kaplan SA**, Koo HP, Olsson CA, Shabsigh R: Neurotrophins in the rat penis I: A developmental study. *J Urol* 152 (6): 2167 -72, 1994.
38. **Kaplan SA**, Te AE and Jacobs BZ: Urodynamic evidence of vesical neck obstruction in men with "chronic non-bacterial" prostatitis and the therapeutic role of endoscopic incision of the bladder neck. *J. Urol* 152 (6):2063-5, 1994.

39. Oesterling JE, **Kaplan SA**, Epstein HB, DeFalco AF and the North American Experience with the Urolume Endoprosthesis as a treatment for benign prostatic hyperplasia: Long term results. *Urology* 44 (3): 353-62, 1994.
40. **Kaplan SA**, Te AE, Blaivas JG: Urodynamic findings in diabetic cystopathy: Surprising results. *J. Urol.* 153 (2):342-4, 1995.
41. Goluboff E, Chang D, Olsson CA, **Kaplan SA** : Urodynamics and the etiology of post - prostatectomy incontinence. *J Urol* 153 (3): 1034-7, 1995.
42. **Kaplan SA**, Goluboff E, Soldo KA, Olsson CA, Dverka PD: Patient choice for symptomatic prostatism. *Urology*, 45:398, 1995.
43. **Kaplan SA**, Soldo KA, Olsson CA: Terazosin and doxazosin in normotensive men with symptomatic prostatism: effect of dosing regimen on efficacy and safety. *Euro Urol* 28 (3) 223-8, 1995.
44. **Kaplan SA**, Chiou RK, Morton WJ, Katz PG and The North American TITAN Stent study group. *Urology* 45 (2):234-40, 1995.
45. **Kaplan SA**, Goluboff ET, Olsson CA, Deverka PA, Chmiel JJ: Effect of demographic factors, urinary peak flow rates, and Boyarsky symptom scores on patient treatment choice in benign prostatic hyperplasia. *Urol* 45 (3) :398-405, 1995.
46. Goluboff E, **Kaplan SA**, Fisch HF: Seminal Vesicle Urinary Reflux as a Complication of Transurethral Resection of the Ejaculatory Ducts. *J. Urol* 153 (4) 1223-5, 1995.
47. **Kaplan SA**, Greenberg R, Baust J: A comparative assessment of cryosurgical devices: application to prostatic disease. *Urol* 1995 45 (4): 692-9, 1995.
48. **Kaplan SA** and Te AE: Uroflowmetry and Multichannel Urodynamics. *Urol Clin N Amer* 22 (2): 309-20, 1995.
49. Te AE and **Kaplan SA**: Transurethral electrovaporization of the prostate (TVP): A novel method of treating men with benign prostatic hyperplasia. *Urol* 45 (4):566-72, 1995.
50. Brisman JL, Kirsch AJ, Taylor JA, Birch BD, Hibshoosh HH and **Kaplan SA** : Pulmonary Lymphangiomyomatosis in tuberous sclerosis: association with chronic renal failure: Case report and review of the literature. *P & S Med Rev*, 2:17, 1994.
51. **Kaplan SA**, and Te AE: Transurethral electrovaporization of the prostate (TVP): An electrosurgical modification of TURP. *Curr Surg Techn* 8 (1): 1-8, 1995.

52. **Kaplan SA**, and Te AE: A comparative study of transurethral resection of the prostate using a modified electrovaporizing loop and transurethral laser vaporization of the prostate. J Urol 154 (5): 1785-90, 1995.
53. **Kaplan SA**, Te AE, Pressler LB and Olsson CA: Transition zone index (TZI), a novel method of assessing benign prostatic hyperplasia: correlation with symptoms, uroflow and detrusor pressure. J Urol 154 (5): 1764-9, 1995.
54. **Kaplan SA**, Meade - D'Alisera P, Quinones S and Soldo K: Doxazosin in physiologically and pharmacologically normotensive men with benign prostatic hyperplasia: a study of safety and efficacy. Urol 46 (4) 512-7, 1995.
55. **Kaplan SA**, Bowers DL, Te AE and Olsson CA: The differential diagnosis of prostatism: a 12 year retrospective analysis of symptoms, urodynamics and satisfaction this therapy. J Urol 155 (4):1305-8, 1996.
56. Roehrborn C, Oesterling JE, Auerbach S, **Kaplan SA**, and the HYCAT Study Group: Effectiveness and safety of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia in the HYCAT study. Urology 47 (2): 159-68, 1996.
57. **Kaplan SA** and Olsson CA: Patient satisfaction with finasteride for the treatment of symptomatic benign prostatic hyperplasia. Clin Ther 18 (1): 73-83, 1996.
58. Te AE and **Kaplan SA**: Electroevaporization of the prostate. Current Opinion in Urology. 6(1) 3 - 9, 1996.
59. **Kaplan SA**, Olsson CA, Te AE: The AHCPR guidelines in the evaluation of men with lower urinary tract symptoms: at 2 years follow - up, does it work? J Urol 155(6): 1971-4, 1996.
60. **Kaplan SA**: Doxazosin in the elderly male patient with hypertension and BPH. Eur Urol. 29: 178 - 181, 1996.
61. **Kaplan SA**, Ikeguchi EF, Santarosa RP, D'Alisera PM, Hendricks J, Te AE and Miller M: Etiology of voiding dysfunction in men < 50 years of age. Urol 47 (6): 836-9, 1996.
62. Reis RB and **Kaplan SA** : Significant correlation of the AUA symptom score and a novel urodynamic parameter: detrusor contraction duration. J Urol. 156:1668 - 1672, 1996.
63. **Kaplan SA** and Santarosa RP, Te AE: Comparison of fascial and vaginal wall slings in the management of intrinsic sphincter deficiency. Urol 47 (6): 885-9, 1996.

64. Te AE, Santarosa R, **Kaplan SA**: Electrovaporization of the prostate: an electrosurgical modification of the standard TURP in 93 patients with BPH. J Endourol 10: 65 - 69, 1996.
65. Lepor H, **Kaplan SA**, Klimberg I, Mobley DF, Fawzy A, Gaffney M, Ice K, Dias N, for the Multicenter Study Group: Doxazosin in benign prostatic hyperplasia: long term efficacy and safety in hypertensive and normotensive patients. J. Urol 57 (2):525-30, 1997.
66. Santarosa RP and **Kaplan SA**: Stress urinary incontinence in women. Brazilian J Urol 13:329 - 337, 1996.
67. **Kaplan SA** and Kaplan NM: Alpha blockade as a monotherapy for both hypertension and BPH. Urol 48 (4): 541-50, 1996.
68. McKiernan J, **Kaplan SA**, Te AE, Santarosa RP and Sawczuk IS: Transurethral electrovaporization of bladder tumors. Urol 48 (2):207-10, 1996.
69. **Kaplan SA**: BPH: Are we too hot for new therapies? J Urol 156 (2 Pt 1):426-7, 1996.
70. **Kaplan SA**, Santarosa RP and Te AE: Transurethral electrovaporization of the prostate: one year experience. Urol 48 (6):876-81., 1996.
71. **Kaplan SA**: Electrovaporization of the prostate: durable modality or passing fad? Urol 49 (2): 157-9, 1997.
72. Klein LT and **Kaplan SA**: Prostatic stents for benign prostatic hyperplasia. J Long Term Complications of Med Implants. J Long Term Compl 7(1): 101- 114, 1997.
73. **Kaplan SA**, Santarosa RP, D'Alisera PM, Fay BJ, Ikeguchi EF, Hendricks J, Klein L, Te AE: "Pseudo" dyssynergia (contraction of the external sphincter during voiding) misdiagnosed as "chronic non - bacterial prostatitis" and the role of biofeedback as a therapeutic option. J Urol. 157:897 - 901, 1997.
74. **Kaplan SA**, Meade D'Alisera P: Tolerability of alpha blockade with doxazosin as a therapeutic option for symptomatic benign prostatic hyperplasia in the elderly patient: a pooled analysis of seven double - blind placebo - controlled studies. Am J Ger 53A (3):M201 – M206, 1998.
75. **Kaplan SA**, Te AE, Ikeguchi E, Santarosa RP: Safety and efficacy of alpha blockers in the treatment of men over the age of 80 with benign prostatic hyperplasia. British Journal of Urology. 1999

76. Mobley D, **Kaplan SA**, Ice K, Gaffney and Dias N: Effect of doxazosin on the symptoms of benign prostatic hyperplasia: results from three double - blind placebo - controlled studies. *Int J Clin Prac.* 51(5), 1997.
77. Sandler P, Avillo C, **Kaplan SA**: Detrusor areflexia in a patient with myasthenia gravis. *Int J Urol.* 5(2): 188 – 190, 1998.
78. **Kaplan SA**, Laor E, Fatal M, Te AE: Transurethral resection of the prostate (TURP) versus transurethral electrovaporization of the prostate (TVP): a blinded, prospective comparative study with 1 year follow - up. *J. Urol.* February, 1998.
79. **Kaplan SA**, Kohn IJ, Te AE and Reis RB: Intermittent alpha blocker therapy in the treatment of men with lower urinary tract symptoms. *Urology*, 52:1, 1998.
80. Shabsigh R, Klein L, Seidman S, **Kaplan SA**, Lehroff B, Ritter J: Increased incidence of depressive symptoms in men with erectile dysfunction. *Urology*, 52(5): 848 – 852, 1998.
81. **Kaplan SA**: Minimally invasive alternative therapeutic options for lower urinary tract symptoms. *Urology*, 51(4A): 32, 1998.
82. **Kaplan SA**, Reis RB, Kohn IJ, Shabsigh R, Te AE: Combination Therapy utilizing oral alpha blockers and intracavernosal injection in men with erectile dysfunction. *Urology*, 52(5): 739, 1998.
83. Reis RB, Te AE, Cologna AJ, Suaid HJ, and **Kaplan SA**: Interstitial thermometry in men undergoing electrovaporization of the prostate. *J Endourol*, 13 (1):53 - 6, 1999.
84. **Kaplan SA**, Staiman VB, Jacobs BZ, Reis B, Te AE: The ratio of transition zone volume to total prostate volume is higher in African - American men than in their Hispanic or Caucasian counterparts. *British Journal Urology*, February, 1999.
85. **Kaplan SA**: Alternative instrumental treatments in BPH electrosurgery. *Eur Urol*, February, 1999.
86. Weiner DM, **Kaplan SA**: Electrosurgery using the Vaportorde. *Eur Urol* 35(2): 166 – 72, 1999.
87. **Kaplan SA**, Reis RB, Kohn IJ, Ikeguchi EF, Laor E, Te AE: Safety and efficacy of sildenafil in women with sexual dysfunction. *Urology*, March, 1999.
88. Roehrborn C, **Kaplan SA**, Waldstreicher J: Serum prostate specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. *Urology*, March, 1999.

89. **Kaplan SA**: Uroselective alpha blockade for BPH: Clinical reality or marketing savvy? *Urology*, 54(5): 776 – 9, 1999.
90. Hayek OR, Shabsigh A, **Kaplan SA** et al: Castration induces acute vasoconstriction of blood vessels in the rat prostate concomitant with a rapid reduction of blood flow. *J Urol.*, 162 (4):1527-31, 1999.
91. Kaplan N, **Kaplan SA**, Quinn S, Grossman EB: Doxazosin mesylate for the treatment of concomitant hypertension and benign prostatic hyperplasia: an open label study in patients with well – controlled hypertension. *Am J. Med.* October, 1999.
92. **Kaplan SA**, Garvin D, Gilhooley P, Koppel M, Labasky R, Milstein R, Reddy P, Rosenberg S, Sussman D, White C, Lee M, Pappas F and Waldstreicher J for the PLESS Study Group. The impact of baseline symptom severity on future risk of BPH – related outcomes and long – term response to finasteride. *Urology*, July 2000.
93. Shabsigh A, Hayek OR, Weiner D, Saidi J, **Kaplan SA**, Kiss A, Burchardt M, Buttyan R, Levin RM: Acute increase in blood flow to the rat bladder subsequent to partial bladder outlet obstruction. *Neurourol Urodynam*, 19:195-206, 2000.
94. **Kaplan SA**, Stifelman M, Avillo C, Reis RB and Te AE: Detrusor contraction duration (DCD) may predict response to alpha blocker therapy for lower urinary tract symptoms. *Eur Urol*, 37 (3):314-317, 2000.
95. **Kaplan SA**, Te AE, Young GHP, Andrade A, Cabelin MA and Ikeguchi EF: Prospective analysis of 373 consecutive women with stress urinary incontinence treated with a vaginal wall sling: the Columbia and Cornell University. *J Urol*, 164:1623 – 1627, 2000.
96. Shabsigh A, Ghafar MA, De la Taille A, Burchardt M, **Kaplan SA**, Anastasiadis AG, Buttyan R: Biomarker analysis demonstrates hypoxic environment in the castrated rat ventral prostate gland. *J Cell Biochem*, 81:437-444, 2001.
97. **Kaplan SA**, Holtgrewe HL, Bruskewitz R, et al: Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia. *Urology*, 57(6): 1073 – 7, 2001.
98. **Kaplan SA**: 5 – alpha reductase inhibitors: what role should they play? *Urology*, 58: 65 – 70, 2001.
99. Choi J, Ikeguchi EF, Lee SW, Choi HY, Te AE, **Kaplan SA**: The high prevalence of benign prostatic hyperplasia related urinary tract symptoms in Korean men is due to a high transition zone index. *Eur. Urol.*, 42 (1): 7 - 11, 2002.

100. **Kaplan SA:** Reproducibility and clinical and concurrent validity of the MSF- 4: a four- item male sexual function questionnaire for patients with benign prostatic hyperplasia. J Urol. 2002 Oct;168(4 Pt 1):1661-2.
101. **Kaplan SA:** Minimally invasive therapies for benign prostatic hyperplasia in the new millennium: long term data J Urol. 2002 Oct;168(4 Pt 1):1661.
102. **Kaplan SA:** Practice trends in the management of prostate disease by family practice physicians and general internists: an Internet-based study. J Urol. 2002 Oct;168(4 Pt 1):1660-1.
103. **Kaplan SA:** Effects of finasteride and cyproterone acetate on hematuria associated with benign prostatic hyperplasia: a prospective, randomized, controlled study. J Urol. 2002 Oct;168(4 Pt 1):1660.
104. **Kaplan SA:** Quality of life of patients on the waiting list for benign prostatic hyperplasia surgery. J Urol. 2002 Oct;168(4 Pt 1):1659-60.
105. **Kaplan SA:** Localization of angiotensin-converting enzyme in the human prostate: pathological expression in benign prostatic hyperplasia. J Urol. Oct;168:1659, 2002.
106. **Kaplan SA:** Characterization of cultured human prostatic epithelial cells by cluster designation antigen expression. J Urol. 2002 Oct;168(4 Pt 1):1658-9.
107. **Kaplan SA:** Effects of meparttricin on estradiol and testosterone serum levels and on prostatic estrogen, androgen and adrenergic receptor concentration in adult rats. J Urol. 168(4 Pt 1):1658, 2002.
108. **Kaplan SA:** Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects. J Urol. 2002 Oct: 168(4 Pt 1):1657-8.
109. **Kaplan SA:** Comparison of long-term results of transurethral incision of the prostate with transurethral resection of the prostate, in patients with benign prostatic hypertrophy. J Urol. 2002 Oct;168(4 Pt 1):1657.
110. Kruzer E and **Kaplan SA:** Cost effectiveness model comparing trimethoprim sulfamethoxazole and ciprofloxacin for the treatment of chronic bacterial prostatitis. European Urology, 42: 163 – 166, 2002.
111. Ghafar MA, Anastasiadis AG, Olsson LE, Chichester P, **Kaplan SA**, Buttyan R, Levin RM : Hypoxia and an angiogenic response in the partially obstructed rat bladder. Laboratory Investigation, 82(7): 903 – 909, 2002.

112. **Kaplan SA:** Increased bladder apoptosis with alpha – 1 adrenoreceptor antagonists in benign prostatic hyperplasia. J Urol 169 (4), 1623, 2003.
113. **Kaplan SA:** Quantitative evaluation of prostatectomy for benign prostatic hypertrophy under a national health insurance law: a multi-centre study. J Urol. 2003 Apr;169(4):1622.
114. **Kaplan SA:** Effects of intrathecal injection of tamsulosin and naftopidil, alpha-1A and 1D adrenergic receptor antagonists, on bladder activity in rats. J Urol 2003, 169 (4): 1621.
115. **Kaplan SA:** Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer. J Urol 2003, 169(4): 1621.
116. **Kaplan SA:** The value of power Doppler imaging to predict the histologic components of benign prostatic hyperplasia. J Urol 2003, 169 (4): 1620.
117. **Kaplan SA:** Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. J Urol. 2003 Apr;169(4):1620.
118. **Kaplan SA:** Association of polymorphisms within androgen receptor, 5 - alpha - reductase and PSA genes with prostate volume, clinical parameters, and endocrine status in elderly men. J Urol. 2003, Apr;169(4):1619.
119. **Kaplan SA:** Office-based transurethral microwave thermotherapy using TherMatrix TMx-2000. J Urol. 2003 Apr;169(4):1618-9.
120. **Kaplan SA, Ghafar MA, Lam JS, Fromer D, Te AE:** Use of finasteride as a diagnostic tool in evaluating men with a serum PSA > 4 and previous negative prostate biopsy. Urology, 60 (3): 464 – 468, 2002.
121. **Kaplan SA:** Soy isoflavonoid equol modulates the growth of benign and malignant prostate epithelial cells in vitro. J Urol 170 (1): 339 – 340, 2003.
122. **Kaplan SA:** Saw palmetto alters nuclear measurements reflecting DNA content in men with symptomatic BPH: evidence for a possible molecular mechanism. J Urol 170 (1): 340, 2003.
123. **Kaplan SA:** Long term (7 – 8 year) experience with finasteride in men with benign prostatic hyperplasia. J Urol 170 (1): 341, 2003.

124. **Kaplan SA:** Holmium laser enucleation for large (greater than 100 ml) prostate glands. J Urol 170 (1): 341 - 342, 2003.
125. **Kaplan SA:** Sexual function in patients treated for benign prostatic hyperplasia reflecting DNA content in men with symptomatic BPH: evidence for a possible molecular mechanism. J Urol 170 (1): 342, 2003.
126. **Kaplan SA:** Transurethral interstitial laser coagulation of the prostate and transurethral microwave thermotherapy vs. transurethral resection or incision of the prostate: results of a randomized controlled study in patients with symptomatic benign prostatic hyperplasia. J Urol 170 (1):342 - 343, 2003.
127. **Kaplan SA:** Serum human glandular kallikrein (hK2) and insulin – like growth factor 1 (IGF – 1) improve the discrimination between prostate cancer and benign prostate hyperplasia in combination with total and % free PSA. J Urol 170 (1): 343, 2003.
128. **Kaplan SA:** Effect of catheter size on urodynamic assessment of bladder outlet obstruction. J Urol 170 (1): 344, 2003.
129. Bautista OM, Kusek JW, Nyberg LM, McConnell JD, Bain R, Miller G, Crawford ED, **Kaplan SA**, Sihelnik SA, Brawer MK, Lepor H for the MTOPS Research Group. Controlled Clinical Trials, 24 (2): 224 – 43, 2003.
130. McConnell JD.....**Kaplan SA**, et al : The long term effect of doxazosin, finasteride and combination therapy on clinical progression of lower urinary tract symptoms and benign prostatic hyperplasia in the Medical Therapy of Prostatic Symptoms (MTOPS) trial. NEJM, December, 2003.
131. **Kaplan SA:** Expression of Colony – stimulating factor 1 receptor during prostate development and prostate cancer progression. J Urol. 170(4): 1475 – 1476, 2003.
132. **Kaplan SA:** Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption / ionization mass spectrometry. J Urol. 170 (4):1476, 2003.
133. **Kaplan SA:** Differentiation of prostate cancer from benign prostate hypertrophy using dual – echo dynamic contrast MR imaging. J Urol. 170 (4): 1476, 2003.
134. **Kaplan SA:** A randomized, double – blind crossover study of tamsulosin and controlled – release doxazosin in patients with benign prostatic hyperplasia. J Urol. 170 (4): 1477, 2003.

135. **Kaplan SA**: Medical Therapy for Asymptomatic Men with BPH: Primum Non Nocere. *Urology*, 62(5):784 – 785, 2003.
136. **Kaplan SA**: Heat versus drugs in the treatment of benign prostatic hyperplasia. *J Urol*. 170 (4): 1477 – 1478, 2003.
137. **Kaplan SA**: Rotoresect for bloodless transurethral resection of the prostate: a 4 – year follow – up. *J Urol*. 170 (4): 1478, 2003.
138. **Kaplan SA**: Benign prostate – specific antigen (BPSA) in serum is increased in benign prostate disease. *J Urol*. 170 (4): 1478 – 1479, 2003.
139. Landis JR, **Kaplan SA**, Swift S: Impact of incontinence severity of antimuscarinic therapy in patients with overactive bladder. *J Urol*, 171(1):752 – 757, 2004.
140. Weissman MM, Gross R, Fryer A, Heiman GA, Gamberoff MJ, Hodge SE, Kaufman D, **Kaplan SA**: Interstitial cystitis and panic disorder: a potential genetic syndrome. *Archives of General Psychiatry*. 61: 273 – 279, 2004.
141. **Kaplan SA**, Volpe M, Te AE: A prospective one – year trial using saw palmetto versus finasteride in the treatment of category III prostatitis / chronic pelvic pain syndrome. *J Urol*, 171:345 – 349, 2004.
142. **Kaplan SA**: Cholinergic innervation and function in the prostate gland. *J Urol*, 171(1): 538, 2004.
143. **Kaplan SA**: Early treatment of benign prostatic hyperplasia: implications for reducing the risk of permanent bladder damage. *J Urol*, 171(1):538 – 539, 2004.
144. **Kaplan SA**: Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care – The Triumph Project. *J Urol*, 171(1): 539 – 540, 2004.
145. **Kaplan SA**: 5 – year outcome of a prospective randomized trial to compare transurethral electrovaporization of the prostate and standard transurethral resection. *J Urol*, 171(1): 540, 2004.
146. **Kaplan SA**: A 4 – year follow – up of a randomized prospective study comparing transurethral electrovaporization of the prostate with neodymium:Yag laser therapy for treating benign prostatic hyperplasia. *J Urol*, 171(1): 540, 2004.
147. **Kaplan SA**: Cooled thermotherapy for the treatment of benign prostatic hyperplasia: durability of results obtained with the Targis system. *J Urol*, 171(1): 541 – 542, 2004.

148. **Kaplan SA:** Minimal transurethral prostatectomy plus bladder neck incision versus standard transurethral prostatectomy in patients with benign prostatic hyperplasia: A randomized prospective study. J Urol, 171(1): 542, 2004.
149. **Kaplan SA:** Comparison of the relaxant effects of alfuzosin, phentolamine and sildenafil on rabbit isolated corpus cavernosum. J Urol, 171(1):542 – 543, 2004.
150. **Kaplan SA:** Insulin – like growth factor I, insulin – like growth factor binding protein 3, and urologic measures of benign prostatic hyperplasia. J Urol, 171(1):543, 2004.
151. **Kaplan SA:** Apoptotic and proliferative index after alpha – 1 – adrenoreceptor antagonist and / or finasteride treatment in benign prostatic hyperplasia. J Urol, 171(1):543 – 544, 2004.
152. **Kaplan SA:** Percent – free prostate specific antigen is elevated in men on hemodialysis or peritoneal dialysis treatment. J Urol, 171(1):544, 2004.
153. **Kaplan SA:** Prostate cancer versus hyperplasia: relationships with prostatic and adipose tissue fatty acid composition. J Urol, 171(1):538, 2004.
154. **Kaplan SA:** BPH management: statistical significance may not translate into clinical relevance. J Urol, 171:1207 – 1208, 2004.
155. **Kaplan SA:** Use and misuse of the concept of quality of life in evaluating surgical treatments for lower urinary tract symptoms. J Urol 171(4): 1751 – 1752, 2004.
156. **Kaplan SA:** Identification of baseline clinical factors which predict medical treatment failure of benign prostatic hyperplasia: an observational cohort study. J Urol 171(4): 1752, 2004.
157. **Kaplan SA:** Long term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers. J Urol 171(4):1752 - 1753, 2004.
158. **Kaplan SA:** Increased discrimination between benign prostatic hyperplasia and prostate cancer with equimolar total prostate specific antigen measurement. J Urol 171(4): 1753 – 1754, 2004.
159. **Kaplan SA:** Benign growth of different prostate zones in aging men with slightly elevated PSA in whom prostate cancer has been excluded: a prospective study of 510 patients. J Urol 171(4):1754, 2004.

160. **Kaplan SA**: Prostatic epithelial and luminal area in the transition zone acini: morphometric analysis in normal and hyperplastic human prostate. *J Urol* 171(4): 1754 – 1755, 2004.
161. **Kaplan SA**: Holmium laser enucleation of the prostate: morbidity in a series of 206 patients. *J Urol* 171(4): 1755, 2004.
162. Sandhu JS, Ng C, Egan C, **Kaplan SA**, Te AE: High-power potassium-titanyl-phosphate (KTP) photoselective laser vaporization of the prostate (PVP) for the treatment of benign prostatic hyperplasia (BPH) in men with large prostates. *Urology*, 64:1155 – 1159, 2004.
163. **Kaplan SA**: Use of alpha adrenergic inhibitors in the treatment of benign prostatic hyperplasia. *Urology*, 63(3): 428 - 435.
164. Walmsley K and **Kaplan SA**: Transurethral microwave thermotherapy (TUMT) for benign prostate hyperplasia (BPH) - Separating truth from marketing hype. *J Urol*, 172(4): 1249 – 1255, 2004.
165. **Kaplan SA**: The long – term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. *J Urol*, 172(1): 413 – 414, 2004.
166. **Kaplan SA**: Use of α – blockers and the risk of hip / femur fractures. *J Urol*, 172(1): 414, 2004.
167. **Kaplan SA**: First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia. *J Urol*, 172(1): 415, 2004.
168. **Kaplan SA**: Phytomedicines for the prostate: *J Urol*, 172(1):415, 2004.
169. **Kaplan SA**: The association between lower urinary tract symptoms and erectile dysfunction in four centres: the UrEpik study. *J Urol*, 172(1):416, 2004.
170. **Kaplan SA**: Variations of transition zone volume and transition zone index after transurethral needle ablation for symptomatic benign prostatic hyperplasia. *J Urol*, 172(1): 416 – 417, 2004.
171. **Kaplan SA**: The effect of urethral instrumentation on uroflowmetry. *J Urol*, 172(1):417 – 418, 2004.
172. **Kaplan SA**: Nd:YAG laser ablation plus transurethral resection for large prostates in high – risk patients. *J Urol*, 172(1):418, 2004.

173. **Kaplan SA:** Transurethral resection vs microwave thermotherapy of the prostate: a cost – consequence analysis. J Urol, 172(1):418 – 419, 2004.
174. **Kaplan SA:** Expression of Protein C Inhibitor (PCI) in benign and malignant prostatic tissues. J Urol, 172(1): 419, 204.
175. **Kaplan SA:** The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia. J Urol, 172(1): 419 – 420, 2004.
176. **Kaplan SA:** Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: A comparative, randomized, two – drug crossover study. J Urol, 172(4):1575, 2004.
177. **Kaplan SA:** Metabolic profile in patients with benign prostate hyperplasia or prostate cancer and normal glucose tolerance. J Urol, 172(4): 1575 – 1576, 2004.
178. **Kaplan SA:** Comparative efficacy of two α_1 - adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement” J Urol, 172(4): 1576 – 1577, 2004.
179. **Kaplan SA:** Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM – 7). J Urol, 172(4):1577, 2004.
180. **Kaplan SA:** Management of acute urinary retention secondary to benign prostatic hyperplasia in the UK: a national survey. J Urol, 172(4): 1577 – 1578, 2004.
181. **Kaplan SA:** Expression of vascular endothelial growth factor receptor – 3 (VEGFR – 3) in human prostate. J Urol, 172(4): 1578, 2004.
182. **Kaplan SA:** Functional and anatomical effects of hormonally induced experimental prostate growth: a urodynamic model of benign prostatic hyperplasia (BPH) in the beagle. J Urol, 172(4): 1579, 2004.
183. **Kaplan SA:** Androgen receptor gene polymorphism and increased risk of urologic measures of benign prostatic hyperplasia. J Urol, 172(4): 1579 – 1580, 2004.
184. **Kaplan SA:** Intra – individual variation of serum prostate specific antigen levels in men with benign prostate biopsies. J Urol, 172(4): 1580, 2004.

185. **Kaplan SA**: Management of inguinal hernia with benign prostatic hyperplasia: simultaneous inguinal hernioplasty with transurethral resection of the prostate. J Urol, 173: 514, 2005.
186. **Kaplan SA**: Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5 α – reductase inhibitor. J Urol, 173: 514 - 515, 2005.
187. **Kaplan SA**: Efficacy and safety of dutasteride in the four – year treatment of men with benign prostatic hyperplasia. J Urol, 173: 515, 2005.
188. **Kaplan SA**: Modeling of the pH – and the temperature – dependent deviations of the free to total PSA (prostate specific antigen) ratios for clinical predictability of prostate cancer and benign prostate hyperplasia. J Urol, 173(4): 1266, 2005.
189. **Kaplan SA**: Updated meta- analysis of clinical trial of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia. J Urol, J Urol 173: 516, 2005.
190. **Kaplan SA**: Apoptosis incidence and protein expression of p53, TGF – β receptor II, p27^{kip1}, and Smad4 in benign, premalignant and malignant human prostate. J Urol, 173(3): 912 – 913, 2005.
191. **Kaplan SA**: Interleukin – 8 expression is increased in senescent prostatic epithelial cells and promotes the development of benign prostatic hyperplasia. J Urol, 173(3): 913, 2005.
192. **Kaplan SA**: Reduction of rat prostate weight by combined quercetin - finasteride treatment is associated with cell cycle deregulation. J Urol, 173(3): 914, 2005. in press.
193. **Kaplan SA**: Prostate – specific antigen in the assessment of organ donors. J Urol, 173(1): 161, 2005.
194. **Kaplan SA**: Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. J Urol, 173(1): 161, 2005.
195. **Kaplan SA** and Neutel J: Vasodilatory factors in the treatment of older men with symptomatic benign prostatic hyperplasia. J Urol in press.
196. **Kaplan SA**: The relation of lower urinary tract symptoms with life style factors and objective measures of benign prostatic enlargement and obstruction: An Italian survey. J. Urol, 173(6):2058, 2005.

197. **Kaplan SA:** Evaluation of the clinical benefit of Permixon and tamsulosin in severe BPH patients – PERMAL study subset analysis. *J Urol*, 173(5):1667 - 1668, 2005.
198. **Kaplan SA:** The role of lipido – sterolic extract of *Serenoa repens* in the management of lower urinary tract symptoms associated with benign prostatic hyperplasia. *J Urol*, 173(5):1667, 2005.
199. **Kaplan SA:** Lycopene: modes of action to promote prostate health. *J Urol*, 173(5): 1667, 2005.
200. **Kaplan SA:** Optimizing the medical management of benign prostatic hyperplasia. *J Urol*, 173(5):1666 – 1667, 2005.
201. **Kaplan SA:** Andropause: endocrinology, erectile dysfunction, and prostate physiology. *J Urol*, 173(5):2058 – 2059, 2005.
202. **Kaplan SA:** Are indications for prostatectomy in octogenarians the same as for younger men? *J Urol*, 173(5):2059, 2005.
203. **Kaplan SA:** Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase – 2, Bcl – 2 and cell proliferation in the glandular epithelium. *J Urol*, 173(4): 1266 – 1267, 2005.
204. **Kaplan SA:** The effect of combined androgen ablation on the expression of alpha_{1A} – adrenergic receptor in the human prostate. *J Urol*, 173(4): 1267, 2005.
205. **Kaplan SA:** Three – year follow – up of feedback microwave thermotherapy versus TURP for clinical BPH: a prospective randomized multicenter study. *J Urol*, 173(5): 1667 – 1668, 2005.
206. Abrams PS, **Kaplan SA**, De Koning HJ, Millard R: Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. *J. Urol.* in press.
207. **Kaplan SA**, Walmsley K, Te AE: Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. *J Urol*, 174: 2273 – 2276, 2005.
208. **Kaplan SA**, McConnell JD, Roehrborn CG, Meehan AG, Lee MW, Noble WR, Kusek JW, Nyberg LM, for the MTOPS Research group. Relationship between prostate size and the effect of combination therapy with doxazosin and finasteride versus either drug alone on the clinical progression of benign prostatic hyperplasia. *J Urol*, in press.

209. **Kaplan SA:** In vitro assessment of the efficacy of thermal therapy in human benign prostatic hyperplasia. J Urol, in press
210. **Kaplan SA:** High – energy transurethral microwave thermotherapy in patients with benign prostatic hyperplasia: comparative study between 30 and 60 minute single treatments. J Urol, 174(4): 1352, 2005.
211. **Kaplan SA:** Transurethral microwave thermotherapy vs. transurethral resection for treating benign prostatic hyperplasia: a systematic review. J Urol, 174(1):221 – 222, 2005.
212. **Kaplan SA:** Intermittent catheterization time required after interstitial laser coagulation of the prostate. J Urol, 174(1): 222, 2005.
213. **Kaplan SA:** The changing practice of transurethral prostatectomy: a comparison of cases performed in 1990 and 2000. J Urol, 174(1):221, 2005.
214. **Kaplan SA:** Development and validation of a quality – of – life scale for Chinese patients with benign prostatic hyperplasia. J Urol, in press.
215. **Kaplan SA:** Single – blind, randomized controlled study of the clinical and urodynamic effects of an α – blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia. J Urol, 174(3): 1011, 2005.
216. **Kaplan SA:** Correlation between lower urinary tract symptoms and urethral function in benign prostatic hyperplasia. J Urol, 174(3): 1010 – 1011, 2005.
217. **Kaplan SA:** Induction and function of CYR61 (CCNI) in prostatic stromal and epithelial cells: CYR61 is required for prostatic cell proliferation. J Urol, 174(3): 1012.
218. **Kaplan SA:** BPH: Patient perceptions and financial reality regarding the aging American prostate. J Urol, 173(5):1852, 2005.
219. **Kaplan SA:** Efficacy of extended – release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction. J Urol, 174 (4): 1353, 2005.
220. **Kaplan SA:** Lower urinary tract symptoms: a hermeneutic phenomenological study into men’s lived experience. J Urol, 174(4): 1353 – 1354, 2005.
221. **Kaplan SA:** Prospective randomized controlled trial comparing plasmakinetic vaporessection and conventional transurethral resection of the prostate. J Urol, in press.

222. **Kaplan SA:** The 12 – year outcome analysis of an endourethral wallstent for treating benign prostatic hyperplasia. J Urol, 174(4): 1354 – 1355, 2005.
223. **Kaplan SA:** Three – dimensional ultrasonography in evaluation of benign prostatic hyperplasia. J Urol, in press.
224. **Kaplan SA:** Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. J Urol, in press.
225. **Kaplan SA:** Patients with a large prostate show a higher prevalence of androgenic alopecia. J Urol, in press.
226. **Kaplan SA:** Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase – 2, Bcl – 2, and cell proliferation in the glandular epithelium. J Urol, 174:2281, 2005.
227. **Kaplan SA:** Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5 α – reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia. J Urol, 174:2282, 2005.
228. **Kaplan SA:** A comparison of four different α 1 – blockers in benign prostate hyperplasia patients with and without diabetes. J Urol, 174:2282 – 2283, 2005.
229. **Kaplan SA** and Neutel J: Factors in the treatment of older men with symptomatic benign prostatic hyperplasia. Urology, in press.
230. **Kaplan SA,** Walmsley K and Te AE: Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol, in press.
231. Capodice JL, Bemis DL, Buttyan R, **Kaplan SA,** Katz AE: A literature review of complementary and alternative medicine for chronic prostatitis / chronic pelvic pain syndrome. Evidence based complementary and alternative medicine. <http://ecam.oxfordjournals.org>. October, 2005
232. **Kaplan SA,** DeRose AF, Kirby RS, O’Leary MP, McVary KT: Beneficial effects of extended-release doxazosin and doxazosin standard on sexual health. BJU International. in press.
233. Giulliano F, **Kaplan SA,** Cabanis MJ: Hemodynamic interaction study between the α ₁-blocker alfuzosin and the phosphodiesterase 5 inhibitor tadalafil in middle-aged healthy male subjects. Urology, in press.

234. **Kaplan SA,** Roehrborn CG, Dmochowski R, Rovner ES, Wang JT, Guan Z: Tolterodine extended release improves overactive bladder symptoms in continent men with overactive bladder and nocturia. *Urology*, in press.
235. **Kaplan SA,** De Rose AF, Kirby RS, O'Leary MP, McVary KT: Beneficial effects of extended – release doxazosin versus doxazosin standard on sexual health. *BJU International*, in press.
236. **Kaplan SA:** Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. *J Urol*, in press.
237. **Kaplan SA:** Expression of cyclooxygenase – 1 and cyclooxygenase – 2 in the human prostate. *J Urol*, in press.
238. **Kaplan SA:** Feedback microwave thermotherapy with the ProstaLund compact device for obstructive benign prostatic hyperplasia: 12 month response rates and complications. *J Urol*, in press.
239. **Kaplan SA:** Intraoperative floppy iris syndrome associated with tamsulosin. *J Urol*, in press.
240. **Kaplan SA:** Prostate size influences the outcome after presenting with acute urinary retention. *J Urol*, in press.
241. **Kaplan SA:** Evaluation of the transurethral ethanol ablation of the prostate (TEAP) for symptomatic benign prostatic hyperplasia (BPH): A European multi – center evaluation. *J Urol*, in press.
242. **Kaplan SA:** Acute urinary retention: what is the impact on patients' quality of life? *J Urol*, in press.
243. **Kaplan SA:** Assessing prostate volume by magnetic resonance imaging. *J Urol*, in press.
244. **Kaplan SA:** Urgency of micturition and detrusor contractility in men with prostatic obstruction and overactive bladders. *J Urol*, in press.
245. **Kaplan SA:** Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). *J Urol*, in press.
246. **Kaplan SA:** Activation of Caspases – 3, - 6, and - 9 during finasteride treatment of benign prostatic hyperplasia. *J Urol*, in press.

247. Roehrborn CG, Abrams P, Rovner ES, **Kaplan SA**, Herschorn S, Guan Z: Efficacy and tolerability of tolterodine extended release in male patients with overactive bladder and urgency urinary incontinence. BJU International, in press.
248. **Kaplan SA** and Crawford ED: Choosing a safe strategy for androgen supplementation in men with low testosterone levels associated with the metabolic syndrome and/or type 2 diabetes. Diabetes Care, in press.
249. **Kaplan SA**, Meehan AG, Shah A: The age-related decline in testosterone is significantly exacerbated in obese men with the metabolic syndrome? What are the implications of this for the relatively high incidence of erectile dysfunction observed in these men?" J Urol, submitted

Invited Articles

1. **Kaplan SA**, Blaivas JG: Bladder dysfunction in patients with multiple sclerosis. Contemporary Urology. 2:14 - 19, 1989.
2. **Kaplan SA**, Brown WC, Blaivas JG: Management of bladder dysfunction in stroke patients. Contemporary Urology. 47 - 50, 1990.
3. **Kaplan SA**, Blaivas JG: Management of BPH. Hospital Medicine. May 77 - 86, 1990.
4. Chancellor MB, **Kaplan SA**, Blaivas JG: Detrusor-external sphincter dyssynergia. CIBA Symposium, Neurobiology of Incontinence, June, 1990.
5. **Kaplan SA**, Koo HP: Prostatic Stents. In: Surgical Techniques in Urology. Volume 3: Issue 4 October, 1990.
6. **Kaplan SA** and Lepor H: Prostate treatment without surgery. Executive Good Health Report, 1990.
7. Stein BS, Stone NN and **Kaplan SA**: Update on Prostatic Disease: Benign Prostatic hyperplasia. Miles Publications. 1991.
8. **Kaplan SA**, Ring KS, Sawczuk, IS: The use of a titanium prostatic stent in the management of acute urinary retention. Video Urology June 1991.
9. **Kaplan SA**, Te A: Bladder dysfunction in diabetes. Problems in Urology. September, 1992.
10. **Kaplan SA**, Ring KS, Sawczuk IS: Titanium Stent in urinary retention. Video Urology Times. 5:1, 1992.

11. **Kaplan SA**: Transrectal hyperthermia in the management of benign prostatic hyperplasia. Urologie, September, 1992.
12. **Kaplan SA**: Transrectal hyperthermia: Current Concepts. Contemporary Urology. March, 1993.
13. **Kaplan SA**: Prostatic urethral stents. Contemporary Urology. April, 1993.
14. **Kaplan SA**: Evaluation: the role of symptoms and urodynamic evaluation of benign prostatic hypertrophy. AUA/Merck Consultant Urologist, 1993.
15. **Kaplan SA**, Shabsigh R, Soldo KA and Olsson CA: Prostatic and Periprostatic Interstitial Temperature Measurements Treated with Transrectal Thermal Therapy (Local Intracavitary Microwave Hyperthermia). Urology/Nephrology Digest, March, 1993
16. **Kaplan SA**: Prostatic urethral stents. Semi Urol 12 (3):193-9, 1994.
17. Te AE and **Kaplan SA**: Transurethral electrovaporization of the prostate (TVP): A novel modification of the standard TURP. Cont Urol 1995 May 7:74-83.
18. Te AE and **Kaplan SA**: Electroevaporization of the prostate. Video Urology. October, 1995
19. **Kaplan SA**: BPH: Options for Care. AUA Today. September, 1995.
20. Te AE and **Kaplan SA**: Transurethral electrovaporization of the prostate: State of the art electrosurgery. Current Opinion in Urology. January, 1997.
21. Santarosa RP, Te AE and **Kaplan SA**: Minimally invasive procedures for benign prostatic hyperplasia: electrovaporization, lasers, heat therapy and stents. In: Mediguide for Urology. Ed: Carson CC. 1996; 9:1-6.
22. Santarosa RP and **Kaplan SA**: Modified vaginal - wall sling for repair of vaginal prolapse. Current Surgical Techniques in Urology. July, 1996.
23. Santarosa RP and **Kaplan SA**: Urology Board review - BPH. Hospital Physician, November, 1996.
24. **Kaplan SA**: BPH: Where are we in 1996? AUA Today. 1:3 1996.
25. Hendricks JG and **Kaplan SA**: Erectile dysfunction and incontinence after radical retropubic prostatectomy. Contemporary Urology, 9:13 - 22, 1997.

26. **Kaplan SA**: Urodynamic and clinical effects of terazosin therapy in symptomatic patients with and without bladder outlet obstruction. Editorial. *Urology*. 49:431, 1997.
27. **Kaplan SA**: The postoperative morbidity of transurethral resection of the prostate and of four "minimally invasive" treatment alternatives. Editorial Comment. *J Urol*, 158:105, 1997.
28. **Kaplan SA**: Voiding symptoms: Why do men under the age of 50 have them? *Issues in Incontinence* 4:1, 1997.
29. Te AE and **Kaplan SA**: Electrovaporization of the Prostate. *Endourology on CD - ROM*. 1:1, 1997.
30. **Kaplan SA** and Goluboff EG: Urology Board Review - Neurogenic Bladder (part 1). *Hospital Physician*, May (volume 5), 1997.
31. Te AE and **Kaplan SA**: Electrovaporization of the prostate. *Mayo Clinic Proceedings*. 73:691 – 695, 1998.
32. **Kaplan SA**: Pharmacologic Management of BPH. *AUA Today*. October, 1997.
33. **Kaplan SA** and Klein LT: Practical Cases in Urology - Practical Management of BPH. In press.
34. **Kaplan SA**: Management of high – risk patients with benign prostatic hyperplasia: Long – term experiences with the Memotherm stent. Editorial comment. *J Urol*, 1998.
35. Cooper KL, McKiernan JM, **Kaplan SA**: Alpha adrenoreceptor antagonists in the treatment of benign prostatic hyperplasia. *DRUGS*, January 57 (1): 9- 17, 1999.
36. **Kaplan SA**: Transurethral resection of the prostate vs. transurethral electrovaporization of the prostate: A blinded, prospective comparative study with 1 – year follows – up. Response to letter. *J. Urol*, November, 1998.
37. Kohn IJ and **Kaplan SA**: The potential clinical utility of iontophoretic drug delivery for urologic procedures. *Contemporary Urology*, November, 1998.
38. **Kaplan SA**: The impact of the new paradigm in pharmacological management. *New Concepts in the medical management of BPH*. Johns Hopkins Press, 1998.
39. Kohn IJ and **Kaplan SA**: Female sexual dysfunction: what is known and what remains to be determined. *Contemporary Urology*. October, 1999.

40. **Kaplan SA**: Benign prostatic hyperplasia: transurethral treatment. Objectives for Urology Residency Education. Ed: Wein, AJ. 1999.
41. Choi J, Ikeguchi EF, Te AE, **Kaplan SA**: Review of laser prostatectomy. Urology Review, July, 1999.
42. Kohn IJ and **Kaplan SA**: Female sexual dysfunction: what is known and what remains to be determined. Contemporary OB/GYN. Vol 45:2, 2000.
43. Cabelin MA, Te AE, **Kaplan SA**: Benign prostatic hyperplasia: Challenges for the new millennium. Current Opinion in Urology. 10:301-306, 2000.
44. Cabelin MA, Te AE, **Kaplan SA**: Transurethral electrovaporization of the prostate. Current Opinion in Urology. 10:306 – 310, 2000.
45. **Kaplan SA**: What makes us different? Curr Urol Rep 1(1): 1 – 2, 2000.
46. **Kaplan SA**: Benign prostatic hyperplasia: many new options, same old approach. Curr Urol Rep 1(2):83, 2000.
47. Cabelin MA, Te AE, **Kaplan SA**: Transurethral electrovaporization of the prostate. Current Urology Reports. 1(2): 116 – 23, 2000.
48. Volpe MA, Fromer D, **Kaplan SA**: Holmium and interstitial lasers for the treatment of BPH: a laser revival. Current Opinion in Urology. 11(1): 43 – 8, 2001.
49. Cabelin M and **Kaplan SA**: Benign prostate hyperplasia: Update on new technology. Contemporary Urology. May, 2001.
50. **Kaplan SA**: Human comfort: more than modern technology. Curr Urol Rep 2(6): 413 – 414, 2001.
51. Blute ML, Jacobsen SJ, **Kaplan SA**, Lowe FC, O’Leary MP, Steers WD, Roehrborn, CG: Introduction to new therapies for BPH. Urology, 58(6) 1 – 4, 2001.
52. Fromer D and **Kaplan SA**: Benign prostatic hyperplasia. In: Conn’s textbook of Medicine. 2002.
53. **Kaplan SA**: Female Sexual dysfunction. Patient Care, February, 2002.
54. Lam J, Volpe, **Kaplan SA**: Stents in the management of men with BPH. Current Urology Reports, 2 (4): 277 – 84, 2001.
55. Littlejohn JO, Ghafar MA, Kang YM, **Kaplan SA**: TURP: The new old standard. Current Opinion in Urology. 2002, 12:19 – 23.

56. Lam JS, Volpe MA, **Kaplan SA**: Transurethral resection and incision of the prostate. Atlas of the Urologic Clinics of North America 10: 27 – 43, 2002.
57. Cabelin MA, Ghafar MA, Te AE, **Kaplan SA**: Transurethral vaporization of the prostate. Atlas of the Urologic Clinics of North America 10: 45 – 49, 2002.
58. **Kaplan SA**: Alpha blocker therapy for BPH. AUA News, November 2002.
59. Littlejohn JO and **Kaplan SA**: An unexpected association between urinary incontinence, depression, and sexual dysfunction. Drugs Today, February, 2003.
60. Ogiste JS, Cooper KL, **Kaplan SA**: Are stents still a useful therapy for BPH? Current Opinion in Urology, 13 (1): 51 – 57, 2003.
61. **Kaplan SA**: BPH medical therapy_in 2003. AUA News, April, 2003.
62. Kohn IJ, Te AE, **Kaplan SA**: Electrical stimulation and neuromodulation in the treatment of lower urinary tract dysfunction. AUA Updates, Volume XXII, #9, 2003.
63. **Kaplan SA**: Men's health: new insights into BPH and sexual function. Medical Education Resources, September, 2003.
64. **Kaplan SA**: Molecular marker for interstitial cystitis. AUA News, September, 2003.
65. Cooper KL, Anastasiadis AG and **Kaplan SA**: Minimally invasive therapies for BPH: variations of the same theme? Contemporary Urology, April, 2004.
66. Lam JS, Cooper KL, **Kaplan SA**: Changing aspects in the evaluation and treatment of patients with benign prostatic hyperplasia. Medical Clinics of North America, 88 (2):281 – 309, 2004.
67. **Kaplan SA**: BPH : new paradigms, new approaches. Urology Times 31(11), 2003.
68. **Kaplan SA**: Medical management of BPH: New paradigms, new approaches. Urology Times, November, 2003.
69. **Kaplan SA**: Prostate histopathology. J Urol, 171:1385, 2004.
70. Gjertsen CK, Walmsley K, **Kaplan SA**: BPH: An update on diagnosis and therapeutic options. Cleveland Clinic Review, 71(11), 2004.
71. Walmsley K, Gjersten CK, **Kaplan SA**: Medical management of BPH – an update. AUA Update, November, 2004.

72. **Kaplan SA:** BPH management in 2004. AUA News, November 2004.
73. **Kaplan SA:** Concomitant use of an artificial urinary sphincter device and a Urolume for men with sphincteric incontinence. AUA News, December, 2004.
74. **Kaplan SA:** An update of the AUA Guidelines. Medical Reviews, 7(6): 324 -354, 2004.
75. **Kaplan SA:** The relationship between sexual function and voiding function: implications for diagnosis and treatment. AUA News, March, 2005.
76. Jaffe W and **Kaplan SA:** The Epidemiology and Pathophysiology of Benign Prostatic Hyperplasia. Atlas of the Prostate, 3rd edition. July, 2005.
77. **Kaplan SA:** Factors predicting failure with medical therapy for BPH. Medical Reviews. 7(7): 534 – 539, 2005.
78. **Kaplan SA:** Alpha blocker therapy: Current Update. Medical Reviews, 7(8):534 – 542, 2005.
79. Rusnack SL, **Kaplan SA:** The use of botulinum toxin in men with benign prostatic hyperplasia. Medical Reviews, in press.
80. **Kaplan SA:** Association between LUTS and sexual function. Scientific World Journal. In press.
81. **Kaplan SA:** The role of muscarinic receptor antagonists in the treatment of men with lower urinary tract symptoms secondary to BPH. American Journal of Urology, in press.

Book Chapters

1. Hensle TW, **Kaplan SA:** Surgical on the lower ureter: an overview. In: Genitourinary Surgery. Ed: Droller. 1991.
2. Hensle TW, **Kaplan SA:** Lower ureteral reconstruction and reimplantation. In: Genitourinary Surgery. Ed: Droller. 1991.
3. **Kaplan SA,** Benson MC: The urologic manifestations of AIDS. AIDS and Rehabilitative Medicine. Ed. Mukand JM. McGraw-Hill. 1992.
4. **Kaplan SA:** Bladder dysfunction. Lebovitz H. Ed., Therapy for Diabetes Mellitus and Related Disorders. American Diabetes Association. page: 288, 1992.

5. **Kaplan SA**: Prostatic Endoprostheses: In: Alternative Treatment of BPH. Ed: Vaughan ED and Romas N: May, 1993.
6. **Kaplan SA**: The neurogenic bladder. Current Therapy in Urology. Ed.: Steer WD. Gower Press. 1993
7. **Kaplan SA**: Non-medical alternative therapy in BPH. In: Nephrology and Urology in the Aged Patient. Oreopolous DG, Michelis, MF and Herschorn, S (eds.). Ch. 58, pp:523-44, 1993.
8. **Kaplan SA**, Blaivas JG, Bruer A: Urogenital physiology. In: Rehabilitation Medicine. Ed: Downey. January, 1994.
9. **Kaplan SA**, Dowd, JB: Non medical, alternative therapy for BPH. In: Handbook for BPH, Ed: Chisolm, G. Raven-Gower press, New York. May, 1994.
10. **Kaplan SA**, Blaivas JG: The evaluation and management of the neurogenic bladder. Pang D (ed.) Disorders of the Pediatric Spine. Raven Press, 1994.
11. Kennedy WC, **Kaplan SA**, Benson MC: Renal and Urologic Aspects of HIV Infection. In: HIV and the Kidney. Eds: Kimmel PL and Berns. Churchill Livingstone, 1994.
12. Te AE and **Kaplan SA**: Pharmaceutical treatment of BPH and its effect on indications for prostate surgery. Surgical Technology International, 3rd Edition. Szabo Z, Kerstein MD, Lewis JE, Eds. Universal Medical Press, Inc. San Francisco, 1994.
13. **Kaplan SA** and Bowers DL: Themotherapy of the prostate: transrectal hyperthermia. Smith's Textbook of Endourology. Eds: Smith A and Badlani GH. 1996.
14. **Kaplan SA**: Prostatic endoprosthetics. In: Textbook of Endourology. Eds: Sosa E, Albala DM, Jenkins AD, Perlmutter AP. WB Saunders, 1996.
15. Te AE and **Kaplan SA**: Urodynamics in BPH. In: Textbook of Benign Prostatic Hyperplasia. Eds: Kirby RS, McConnell JD, Fitzpatrick JM, Roehrborn CG, Boyle P. Isis Medical Media Ltd., Oxford, England. 1996.
16. Te AE and **Kaplan SA**: Prostatic endoprosthetics. In: Textbook of Benign Prostatic Hyperplasia. Eds: Kirby RS, McConnell JD, Fitzpatrick JM, Roehrborn CG, Boyle P. Isis Medical Media Ltd, Oxford, England. 1996.
17. Gibbons RP, Altwein JE, Bruskewitz RC, Choquet C, Costello AJ, Flam TA, Fourcade RO, Koshiba K, McNicholas TA, Stein BS, **Kaplan SA**: Surgical and Laser Treatment. 3rd International Consultation on Benign Prostatic Hyperplasia. ED: Cockett ATK, Khoury S, Aso Chatelain C, Denis L, Griffiths K, Murphy G. SCI Ltd., 1996.

18. **Kaplan SA** and Jacobs BZ: Urinary incontinence in patients with Parkinson's Disease. In: Parkinson's Disease. Kuttcher, A. 1996
19. Santarosa RP and **Kaplan SA**: Transurethral resection of the prostate. In: Operative Urology. Eds: Krane RJ, Fitzpatrick J, Siroky MB. Churchill Livingstone, 1996.
20. Te AE and **Kaplan SA**: Electrovaporization principles. In: Prostate Surgery. Ed: Narayan. 1997.
21. Roehrborn CG, Andersen JT, Correa R, Di Silverio F, **Kaplan SA**, Kurth KH, Rubben H, Torp - Pedersen ST, Watanabe H, Zerbib M: Initial diagnostic evaluation of men with lower urinary tract symptoms. 3rd International Consultation on Benign Prostatic Hyperplasia. ED: Cockett ATK, Khoury S, Aso Y, Chatelain C, Denis L, Griffiths K, Murphy G. SCI Ltd., 1996.
22. Santarosa RP, Te AE, **Kaplan SA**: Transurethral resection, incision and ablation of the prostate. Glenn's Urologic Surgery, 5th edition. Ed. Graham SD. 1997.
23. Staiman VR and **Kaplan SA**: Bladder dysfunction. Lebovitz H. Ed., Therapy for Diabetes Mellitus and Related Disorders. American Diabetes Association. page: 288, 1997.
24. Te AE, Santarosa RP, **Kaplan SA**: Electrovaporization of the prostate: advanced application of electrosurgical principles to the treatment of benign prostatic hyperplasia, In: Recent Advances in Urology. ED: Kirby RS, O'Leary MP, Churchill Livingstone, 1998.
25. Te AE and **Kaplan SA**: Complications of Minimally Invasive Surgery for BPH. In: Complications in Urologic Surgery. Eds: Taneja, Smith & Ehrlich. 2000.
26. Kohn I and **Kaplan SA**: Medical therapy of BPH. Atlas of Clinical Urology. Eds. Vaughan ED and Perlmutter A. 2000.
27. Kohn IJ and **Kaplan SA**: Lower urinary tract obstruction. In: Surgery. EDS: Carson CC, 2001.
28. Kohn IJ, Te AE and **Kaplan SA**: Urodynamics of prostatitis. In: Textbook of prostatitis. EDS: Nickel JC. 2000.
29. Te AE, Ikeguchi EF, Choi J, **Kaplan SA**: Urodynamics and benign prostatic hyperplasia. In: Textbook of benign prostatic hyperplasia. Eds: Kirby RS, McConnell JD, Fitzpatrick JM, Roehrborn CG, Boyle P. Isis Medical Media Ltd., Oxford, England. 2000.

30. Cabelin M, Te AE and **Kaplan SA**: Urogenital physiology. In: Rehabilitation Medicine. Ed: Downey and Leiberan. 2000.
31. Knowles D, Volpe M and **Kaplan SA**: Sexual dysfunction. In: Pelvic Disorders. Ed: Bourcier AP, McGuire EJ and Abrams P. Harcourt Health Sciences (WB Saunders), Philadelphia, PA. 2001.
32. Littlejohn JO, Kang YM, **Kaplan SA**: Transurethral vaporization of the prostate. In: Management of Benign Prostatic Hypertrophy. ED: McVary KT. Humana Press. 2004
33. Cooper KL, **Kaplan SA**: Overactive Bladder and Incontinence. In: Men's Health volume 2. Eds: Kirby RS, Carson C, Kirby MG, Farah RN. Martin Dunitz, London, 2003 (In Press, Fall 2003)
34. Walmsley K, Gjersten CK, **Kaplan SA**: Medical management of BPH – an update. Campbell's Urology. Volume 2, Number 2, 2004.

ABSTRACTS (Total of 123)

- 1) Olsson CA, **Kaplan SA**: Contemporary cystectomy versus radiation therapy plus cystectomy for bladder cancer. J Urol 135:222A, 1986.
- 2) Benson MC, **Kaplan SA**: Identification of subtle degrees of tumor aneuploidy utilizing a new flow cytometric method. J. Urol., 137:217A., 1986
- 3) **Kaplan SA**, Olsson CA, Karp F, Benson MC: Comparison of urine and bladder barbotage in the flow cytometric detection of TCC in the bladder. J Urol, 139:322A, 1988.
- 4) **Kaplan SA**, Hensle TW, Burbige KA, Sandberg DE: Hypospadias: associated behavior problems and male gender role development. J Urol 141:172A, 1989.
- 5) Brown WC, Sarky SM, **Kaplan SA**, Blaivas JG: Aging and its effect on parameters of detrusor contractility. J Urol 141:358A, 1989.
- 6) **Kaplan SA**, Chancellor MB, Blaivas JG: A urodynamic evaluation of bladder and sphincter behavior in patients with spinal cord lesions. J Urol 143:371A, 1990.
- 7) Chancellor MB, **Kaplan SA**, Schuessler GB, Blaivas JG: The cholinergic and purinergic components of detrusor contractility in whole rabbit bladder model. J Urol, 143:387A, 1990.
- 8) Shenot PJ, Chancellor MB, Hirsch IH, Blaivas JG, Bhansali LD, **Kaplan SA**: Urodynamic Finding in patients with the Lyme spirochete. J. Urol, 145:66, 1990.

- 9) Dean GE, Blaivas JG, **Kaplan SA**: The differential diagnosis of prostatism. J Urol 145:79, 1991.
- 10) **Kaplan SA**, Blaivas JG, Chancellor MB, Brown WC: Mechanical indices of detrusor contractility in male and female rabbit bladders. J. Urol., 145:381, 1991.
- 11) Koo HP, Buttyan R, Olsson CA, **Kaplan SA**: Sulfated glycoprotein-2 and transforming growth factor-beta expression in diabetic rat bladders: Evidence of acute injury. J. Urol, 145:393, 1991.
- 12) **Kaplan SA**, Blaivas JG, Chancellor MB: The effect of pharmacologic and electrical stimulation on power, work and WF. J. Urol. 145:146, 1991.
- 13) Benson MC, Whang IS, Pantuck A, Ring K, **Kaplan SA**, Olsson CA, Cooner W: Prostate specific antigen density: A means of distinguishing BPH and prostate cancer. J Urol 145:382A, 1991.
- 14) **Kaplan SA**, Buttyan R, Olsson CA, Koo HP: SGP-2 Expression in diabetic rat bladders: evidence of acute injury. 14th International Diabetes Federation Congress. June 1991.
- 15) Soldo KA, Shabsigh R, Olsson CA, **Kaplan SA**: Applicator-urethral distance and pre-treatment urodynamics as prognostic indicators for patients undergoing transrectal thermal therapy. J Urol, 147:345A, 1992.
- 16) **Kaplan SA**, Soldo KA, Blaivas JG, Olsson CA: Alternative therapy for symptoms of prostatism: What do patients want? J Urol 147:347A, 1992
- 17) Te AE, Buttyan R, Koo HP, Greene LA, **Kaplan SA**, Olsson CA, Shabsigh R: Abundant expression of nerve growth factor (NGF) in the rat penis, a developmental study. J Urol 147:239A, 1992.
- 18) Koo HP, Buttyan R, Te AE, **Kaplan SA**, Olsson CA, Shabsigh R: Neurotrophin expression in diabetic rat penis: a new insight into pathogenesis of diabetic erectile dysfunction. J Urol, 147:240A, 1992.
- 19) **Kaplan SA**, Chiou RE, Katz GP and the North American Titanium Study Group: The titanium prostatic urethral stent: The United States experience. J Urol 147:307A, 1992.
- 20) Shabsigh R, Buttyan R, Koo HP, **Kaplan SA**, Olsson Ca, Te AE: Expression of neurotrophins: nerve growth factor (NGF), brain-derived neurotrophic factor and ciliary neurotrophic factor (CNTF) in the rat penis. J Urol 147:318A, 1992.

- 21) Te AE, Buttyan R, Koo HP, Shabsigh R, Olsson CA, **Kaplan SA**: Nerve growth factor in diabetic cystopathy. J Urol 147:350A, 1992.
- 22) Jacobs BZ, Blaivas JG, **Kaplan SA**: Persistent symptoms following TURP: a urodynamic assessment. J Urol 147:398A, 1992.
- 23) **Kaplan SA**: "Prostatic stents in the management of geriatric men with prostatism. Uroynamics Society, May 1992.
- 24) **Kaplan SA**, Soldo KA, Olsson CA: Daytime versus nighttime dosing of the long acting alpha blockers, terazosin and doxazosin. European Urology Association, July 1992.
- 25) Te AE, Buttyan R, Koo HP, Olsson CA, **Kaplan SA**: Nerve growth factors in diabetic cystopathy. International Continence Society. September 1992.
- 26) **Kaplan SA**, Blaivas JG, Te AE: Urodynamic findings in patients with diabetic and voiding symptoms: Surprising results. International Continence Society. September 1992.
- 27) **Kaplan SA**, and the Doxazosin Multicenter Study Group: Efficacy and safety of the long acting alpha₁ -agonist, doxazosin in hypertensive men with BPH: A dose response study. Uroynamics Society Annual Meeting. May, 1993.
- 28) Chiou RK, Suarez GM, Wadle RW, Gill H, Katz G, Morton WJ, Daugherty JD, **Kaplan SA**: Use of the TITAN intraprostatic stent in men with BPH: preliminary results from the United States National Cooperative Study. J. Urol, 149:216A, 1993.
- 29) Te AE, Buttyan R, Koo HP, **Kaplan SA**, Olsson CA, Shabsigh R: Neurotrophic factors in the diabetic rat penis: an extended study. J. Urol., 149:247A, 1993.
- 30) Koo HP, Santarosa RP, Buttyan R, Shabsigh R, Olsson CA, **Kaplan SA**: Comparison of gene expression in streptozotocin induced diabetic cystopathy and osmotic diuresis in rat bladders. J. Urol., 149:267A, 1993.
- 31) Santarosa R, Colombel M, **Kaplan SA**, Monson F, Levin R, Buttyan R: Regression of the hypertrophied rabbit bladder after release of outlet obstruction involves extensive apoptosis of specific cellular elements. J. Urol., 149:341A, 1993.
- 32) **Kaplan SA**, Olsson CA: Urodynamic evidence of vesical neck obstruction in men with chronic prostatitis and the therapeutic role of TUIP. J. Urol., 149:406A, 1993.
- 33) **Kaplan SA**, Olsson CA, Deverka PA: Patient demographics as prognostic variables for choice of treatment in prostatism. J. Urol., 149:495A, 1993.

- 34) Goluboff E, Chang D, Olsson CA, **Kaplan SA**: Urodynamics and the etiology of post-prostatectomy incontinence. J. Urol., 151: 326A, 1994.
- 35) Santarosa RP, Te AE, Koo HP, Buttyan R, **Kaplan SA**, Olsson CA, Shabsigh R: Androgen deprivation and apoptosis in rat erectile tissue. J. Urol., 494A, 1994.
- 36) **Kaplan SA**, Te AE, Soldo KS, Olsson CA: Use of the AUA-BPH treatment guidelines in men with symptomatic benign prostatic hyperplasia (BPH): at one year does it work? J. Urol., 507A, 1994.
- 37) Miller MI and **Kaplan SA**: A new voiding classification system for evaluation of young men with voiding dysfunction based on urodynamic findings. J. Urol., 272A, 1995
- 38) Te AE, **Kaplan SA**, Dann JA: Transurethral electrovaporization of the prostate (TVP), a novel method for treating men with benign prostatic hyperplasia: comparison to laser TURP. J. Urol., 436A, 1995.
- 39) Te AE and **Kaplan SA**: Transurethral electrovaporization of the prostate (TEVAP). J. Urol., 220A, 1995.
- 40) **Kaplan SA**: Alpha blockade: monotherapy for hypertension and BPH. 3rd International Conference on BPH. Monte Carlo, June 1995.
- 41) **Kaplan SA**, Meade D'Alisera: Doxazosin does not adversely affect blood pressure of physiologically or pharmacologically normotensive patients with benign prostatic hyperplasia. 3rd International Conference on BPH. Monte Carlo, June 1995.
- 42) Bowers DL, Mallory B, Chen MW, O'toole K, **Kaplan SA**: Neurogenic bladder gene expression in female wistar rats after complete spinal cord transection. 1st Congress of the European and American Societies for Basic Urologic Research. Rotterdam, September 1 - 3, 1995.
- 43) Bowers DL, Mallory B, Chen MW, O'toole K, **Kaplan SA**, Connor J: Neurogenic bladder gene expression in female wistar rats after complete spinal cord transection: A model for myelomningocele. American Pediatric Society. San Francisco, October, 1995.
- 44) Reis R and **Kaplan SA**: Interstitial temperature measurements of men undergoing electrovaporization of the prostate. XX Brazilian Urologic Congress, Salvador, Bahia, November, 1995.

- 45) Bowers DL, Connor J, Mallory B, Chen MW, O'Toole K and **Kaplan SA**: Bladder tumor production in female wistar rats: a new tumor model for transitional cell carcinoma. AUA Annual Meeting, Orlando, Florida. May, 1996.
- 46) Avillo C, Bowers DL, Olsson CA and **Kaplan SA**: Men who are continent after prostatectomy have low valsalva leak point pressure: important diagnostic implications. AUA Annual Meeting, Orlando, Florida. May, 1996
- 47) **Kaplan SA**, Santarosa RP and Te AE: Electro vaporization of the prostate for symptomatic benign prostatic hyperplasia: the 1 year experience. AUA annual meeting, Orlando, Florida. May, 1996.
- 48) Reis RB, Cologna AJ, Suaid HJ, **Kaplan SA** and Te AE: Electro vaporization of the prostate (VAP): a comparison of roller electrode configurations for resecting prostate tissue. AUA Annual Meeting, Orlando, Florida. May, 1996.
- 49) Laor E, **Kaplan SA**, Te AE, Tolia BM and Reid RE: Laser vaporization of "large" prostate glands: long term follow - up. AUA annual meeting, Orlando, Florida. May, 1996.
- 50) Reis RB, Cologna AJ, Suaid HJ, Te AE and **Kaplan SA**: Interstitial thermometry in men undergoing electro vaporization: is it safe? AUA annual meeting, Orlando, Florida. May, 1996.
- 51) **Kaplan SA**, Santarosa RP and Te AE: The incidence of hypertension in men with benign prostatic hyperplasia. XIIth European Urology Association, Paris, 1996.
- 52) **Kaplan SA**: The ratio of transition zone to total prostate volume is higher in African - American men than in their Caucasian or hispanic counterparts. XXIIth European Urology Association, Paris, 1996.
- 53) **Kaplan SA**, Laor E and Te AE: Transurethral resection of the prostate (TURP) versus electro vaporization of the prostate (VAP): a prospective, blinded comparative study of the treatment of benign prostatic hyperplasia (BPH). XXIIth European Urology Association, Paris, 1996.
- 54) Avillo C, Stifelman M, Te A, Sandler P and **Kaplan SA**: The urodynamic parameter: detrusor contraction duration (DCD) predicts response to alpha blocker therapy for lower urinary tract symptoms (LUTS). J Urol (157): 534, 1997.
- 55) Te AE, Laor EL, **Kaplan SA**, Babayan R, Noble M, Mbust W, Bruskevitz R, Whitfield HN: Transurethral resection of the prostate (TURP) versus vaporization of the prostate utilizing a vaporizing loop (TVLOOP): a multicenter, blinded, prospective comparative study. J Urol (157): 534, 1220, 1997.

- 56) Te AE, Laor E, and **Kaplan SA**: Transurethral resection of the prostate (TURP) versus transurethral electrovaporization of the prostate (TVP): a blinded, prospective comparative study with 1 year follow - up. J Urol (157): 1226, 1997
- 57) Pressler LB, Santarosa RP, Te AE and **Kaplan SA**: The incidence of hypertension (HTN) in a population of men with benign prostatic hyperplasia (BPH): analysis based on the AUA symptom score and race. J Urol (157): 1453, 1997.
- 58) **Kaplan SA**, Stifelman M and Meade D'Alisera P: Analysis of patient satisfaction with treatment for benign prostatic hyperplasia (BPH) based on race. J Urol (157): 1167, 1997.
- 59) **Kaplan SA**, Short K, Geller J et al: Baseline symptoms determine long-term symptomatic response to finasteride: Results of a four-year, placebo-controlled trial. European Urology Association, February, 1998, Barcelona, Spain.
- 60) D'Alisera PM, Stifelman M, Kohn I, Te AE, Weiner DM, **Kaplan SA**: Correlation of lower urinary tract symptom (LUTS) severity by International Prostate Symptom Score (IPSS) and erectile dysfunction (ED) in men over 50 years of age. J Urol (159): 103, 1998.
- 61) Leiber M, Fowler J, Castellanos R, Albertsen P, Coffield S, Hodge B, Resnick M, **Kaplan SA**, Wang D, Waldstreicher J. : PSA is the strongest predictor of BPH – related outcomes results of a 4 – year placebo – controlled trial. J Urol (159): 107, 1998.
- 62) Finkelstein MB, Houghton WC, Hildebrand KR, **Kaplan SA**: Local delivery of lidocaine to the canine prostate using pressure and iontophoresis with a novel catheter system. J Urol (159): 110, 1998.
- 63) Reis RB, Suaid HJ, Cologna AJ, Te AE, **Kaplan SA**: Men with lower urinary tract symptoms (LUTS) and inguinal hernias (HERN) have significantly greater bladder outlet obstruction (BOO) than men with LUTS alone. J Urol (159): 139, 1998.
- 64) Laor E, McWilliams G, Josifedes H, **Kaplan SA**: Minimally invasive management of large bladder calculi in patients with bladder outlet obstruction and benign prostatic hyperplasia. J Urol (159): 247, 1998.
- 65) **Kaplan SA**, Melman A, Fowler J, et al: Baseline symptom severity and its relationship to long – term response to finasteride. J Urol (159): 254, 1998.

- 66) **Kaplan SA** for the NIH MTOPS Study Group: Medical therapy of prostate symptoms (MTOPS): baseline urodynamic data and correlation with prostate volume and prostate specific antigen (PSA). J Urol (159): 330, 1998.
- 67) Reis RB, Suaid HJ, Cologna A, Martins ACP, Te AE, **Kaplan SA**: Intermittent therapy with alpha blocker, alfuzosin. J Urol (159): 331, 1998. J Urol (159): 103, 1998.
- 68) Shabsigh A, Hayek O, Weiner D, **Kaplan SA**, Burchardt M, Buttyan R: Partial bladder outlet obstruction of the rat rapidly increases bladder blood flow. J Urol 161 (4):871, 237, 1999.
- 69) Shabsigh A, Hayek O, Chen MW, **Kaplan SA**, Burchardt M, Burchardt T, Puchner PJ, Buttyan. Early effects of castration on the vascular system of the rat ventral prostate gland. J Urol 161(4):872, 237, 1999.
- 70) Kohn IJ, Chang D, Ikeguchi EF, **Kaplan SA**: Dual placement of an artificial urinary sphincter (AUS) and a Urolume Wallstent for male sphincteric incontinence (SUI) and recurrent bladder neck contracture. J Urol 161(4):994, 257, 1999.
- 71) **Kaplan SA**, for the PLESS Study Group: Effect of finasteride on filling and voiding symptoms of BPH. J Urol 161(4):1036, 268, 1999.
- 72) Larsen T, Utz W, Bruskewitz R, Mayer R, Blute M, Diokno A, Gibbons R, Wilson J, **Kaplan SA**: U.S. Multicenter study results of targeted transurethral thermo – ablation therapy for benign prostatic hyperplasia (BPH) continues to show improvement in patients’ symptoms and flow rates without compromise in morbidity. J Urol 161(4): 1509, 389, 1999.
- 73) Nejat R, Ikeguchi EF, Te AE, Reis RB, **Kaplan SA**: Electrovaporization of the prostate utilizing the roller ball and / or vaporizing loop for symptomatic benign prostatic hyperplasia (BPH): The 4 – year Columbia experience. J Urol 161(4):1517, 391, 1999.
- 74) Ghafar A, **Kaplan SA**, Shabsigh A, Burchardt M, Burchardt T, Buttyan R: In vivo activation of C-Jun N - terminal kinase signaling pathway during castration - induced apoptosis of rat prostate epithelial cells. J Urol 163(4):944, 213, 2000.
- 75) Kaplan NM and **Kaplan SA**: Doxazosin for the treatment of concomitant hypertension and benign prostatic hyperplasia (BPH): an open - label study in patients with well controlled hypertension. J Urol 163 (4): 979, 220, 2000.

- 76) Choi J, Ikeguchi EF, Lee SW, Choi HY, Te AE, **Kaplan SA**: Characterization of lower urinary tract symptoms and prostate parameters in Asian men compared to Caucasians, Hispanics and African - Americans. J Urol 163(4): 1110, 250, 2000.
- 77) **Kaplan SA**, Larson TR, Utz WJ, Bruskewitz R, Mayer R, Blute M, Diokno AC, McKenzie D, Gibbons R: Combined long term results based on initial prostate size of U.S. multi - center studies using the TARGIS system for benign prostatic hyperplasia. J Urol 163(4): 1188, 268, 2000.
- 78) Williams JC, Conn RL, Kursh ED, Issa MM, Greenberger M, Steiner MS, Camuzzi F, **Kaplan SA**, Vitenson J. One and two year outcomes of interstitial laser coagulation of the prostate in 250 men: a multi - center experience with the Indigo 830e. J Urol 163(4): 1202, 271, 2000.
- 79) Ries RB, Martins ACP, Cologna A, Junior ST, Te AE, **Kaplan SA**: Long term durability of intermittent alpha blockade in the treatment of lower urinary tract symptoms (LUTS). J Urol 163(4): 1362, 2000.
- 80) **Kaplan SA**: The efficacy and safety of finasteride in elderly men with benign prostatic hyperplasia. J Urol 163(4): 1368, 308, 2000.
- 81) **Kaplan SA for the PLESS group**: The efficacy and safety of finasteride in elderly men with benign prostatic hyperplasia. European Urology, 2001.
- 82) Nickel JC.....**Kaplan SA**: Effects of rofecoxib in patients with chronic nonbacterial prostatitis. J Urol, 165 (5) :114, 2001.
- 83) Volpe MA, Cabelin M, Te AE, **Kaplan SA**: A prospective trial using saw palmetto versus finasteride in the treatment of chronic nonbacterial prostatitis (CP). J Urol, 165 (5):115, 2001
- 84) Ghafar MA, Shabsigh A, Anasastasiadis AG, **Kaplan SA**, Buttyan R, Levin RM, Chichester P: Effects of long term bladder outlet obstruction on blood flow to the bladder. J Urol, 165 (5):874, 2001.
- 85) Ghafar MA, Shabsigh A, Anasastasiadis AG, Barach J, Hayek OR, **Kaplan SA**, Buttyan R: The effects of castration on the production of vaso – regulatory substances in the rat prostate gland. J Urol, 165 (5) :875, 2001.
- 86) Te AE, Ghafar MA, Merriweather T, Volpe M, Ikeguchi E, **Kaplan SA**: Nomogram and urodynamic predictors of urinary retention in men with BPH and bladder outlet obstruction. J Urol, 165 (5):1096, 2001.

- 87) **Kaplan SA**, Larson TR, Utz WJ, Bruskewitz R, Mayer R, Diokno AC, Gibbons R, McKenzie D: Combined long term outcomes stratified by patients age at treatment. Results of the Targis system multi – center study for benign prostatic hyperplasia (BPH). J Urol, 165 (5):1215, 2001.
- 88) Ghafar M, Anastasiadis AG, Olsson LE, Chichester P, **Kaplan SA**, Olsson CA, Buttyan RB: Hypoxia and an angiogenic response in the partially obstructed rat bladder. J Urol, 167(4):132, 2002
- 89) Rodgers JM, Te AE, Ghafar MA, **Kaplan SA**, Zaontz MR, Packer M, Dean GE: Glibencalmide enhances stretch – activated contraction in rat bladders and shows protective effects in human diabetic cystopathy. J Urol, 167 (4):169, 2002.
- 90) Cooper K, Littlejohn JO, Te AE, **Kaplan SA**: Disappointing long term results of transvaginal bone anchors in the treatment of stress urinary incontinence (SUI): The 3 – year New York Presbyterian Hospital experience. J Urol, 167 (4):312, 2002.
- 91) Ghafar M, Lam J, Littlejohn JO, **Kaplan SA**: Use of finasteride as a diagnostic tool in evaluating men with a serum PSA > 4 and previous negative prostate biopsy. J Urol, 167 (4):1051, 2002.
- 92) Littlejohn JO, Ghafar MA, **Kaplan SA**: Urodynamic findings in men with DM and BPH. J Urol, 167 (4):1063, 2002.
- 93) **Kaplan SA**, Blute M, Bruskewitz RC, Larson TR, Utz W, Ugarte R, Mayer R: Long term efficacy and durability in 345 patients treated with transurethral microwave thermotherapy for benign prostatic hyperplasia: Five year results. J Urol, 167 (4): 1153, 2002.
- 94) Trock BJ, Brotzman MJ, Utz W, Ugarte R, **Kaplan SA**, Larson TR, Blute M, Roehrborn C, Partin AW: A pooled analysis of multi – center studies of cooled thermotherapy™ for benign prostatic hypertrophy (BPH): Results at 3, 12 and 24 months. J Urol, 167 (4):1155, 2002.
- 95) **Kaplan SA** and Te AE: Electrovaporization of the prostate utilizing the roller ball and / or vaporizing loop for symptomatic benign prostatic hyperplasia (BPH): The 7 – year Columbia experience in 650 consecutive men. J Urol, 167 (4):169, 1437, 2002.
- 96) **Kaplan SA** and Te AE: Pressure / Flow evaluation of ethnically diverse men treated by minimally invasive surgical therapies for BPH: The New York Presbyterian Hospital experience. J Urol, 167 (4):1454, 2002.

- 97) **Kaplan SA** for the International Group on BPH and sexual function.] LUTS and Male Sexual Dysfunction: The Multi-National Survey of the Aging Male. New York Section, American Urological Association, Barcelona, Spain, October, 2002.
- 98) Volpe MA, Shah S, Cooper K, **Kaplan SA**: Illicit ketamine abuse (special K) causing eosinophilic cystitis. J Urol, 169 (4):36, 2003.
- 99) McConnell, JD, Roehrborn CG.....**Kaplan SA** et al: Baseline measures predict the risk of benign prostatic hyperplasia clinical progression in placebo – treated patients. J Urol, 169 (4): 1287, 2003.
- 100) **Kaplan SA**, Roehrborn CG, McConnell JD.....: Baseline symptoms, uroflow, and post void residual urine as predictors of BPH clinical progression in the medically treated arms of MTOPS. J Urol, 169 (4): 1289, 2003.
- 101) **Kaplan SA** for the PLESS Study group: Impact of baseline symptom severity on general health and sexual satisfaction in men with BPH treated with finasteride or placebo. J Urol, 169 (4): 1298, 2003.
- 102) Sandhu JS, Vanderbrink BA, Egan C, **Kaplan SA**, Te AE: High power KTP photoselective laser vaporization prostatectomy for the treatment of benign prostatic hyperplasia in men with large prostates. J Urol, 169 (4): 1470, 2003.
- 103) Cooper KL, Te AE, **Kaplan SA**: Long term safety and efficacy in 147 patients treated with prostate stents for benign prostatic hyperplasia (BPH):12 – year results. J Urol, 169 (4): 1749, 2003.
- 104) Gretzer MB, Trock BT, Utz W, Ugarte R, **Kaplan SA**, Larson T, Blute M, Roehrborn CG, Partin AW: Serum prostate specific antigen levels following transurethral microwave thermotherapy. J Urol, 169 (4): 1756, 2003.
- 105) Okeke Z, Walmsley K, Te AE, **Kaplan SA**: Sexual function in ethnically diverse men Category III prostatitis / chronic pelvic pain syndrome. J Urol 171 (4): 229, 2004.
- 106) **Kaplan SA**, Olsson CA, Gross R, Kaufman D, Gameroff MJ, Weissman MM: Chromosome 13 syndrome: A pleiotropic genetic linkage between panic disorder and interstitial cystitis. J Urol 171 (4): 522, 2004.
- 107) Roehrborn CG, Kusek JW, Nyberg LM, Noble W, Bautista O, McVary KT, Slawin KM, **Kaplan SA**: Impact of baseline symptom severity on threshold changes to trigger crossing over to active therapy in MTOPS trial. J Urol 171 (4):910, 2004.

- 108) Roehrborn CG, McConnell JD, Kusek JW, Nyberg LM, Slawin KM, McVary KT, Dixon CM, **Kaplan SA** and the MTOPS Investigator Group, Noble W: Impact of baseline PSA and TRUS volume on longitudinal changes in IPSS and maximum flowrate in MTOPS. J Urol 171 (4): 911, 2004.
- 109) **Kaplan SA**, Walmsley K, Te AE: Use of muscarinic receptor antagonists as monotherapy in men with lower urinary tract symptoms who failed previous therapy with alpha blockers. J Urol 171 (4): 917, 2004.
- 110) Te AE, **Kaplan SA**: Dutasteride provides improvement in urodynamic parameters over 2 years: analysis of data from the Phase III dutasteride studies. J Urol 171 (4): 1363, 2004.
- 111) Sandhu JS, Ng CK, Gonzalez R, **Kaplan SA**, Te AE: High – power KTP photoselective laser vaporization prostatectomy in men with large prostates: The New York Presbyterian series of 64 patients. J Urol 171 (4): 1522, 2004.
- 112) Te AE, Sandhu JS, Gonzalez R, Egan C, **Kaplan SA**: High – power KTP photoselective laser vaporization prostatectomy (PVP) versus transurethral electrovaporization of the prostate (TVP) for the treatment of benign prostatic hyperplasia (BPH): a prospective comparative trial. J Urol 171 (4): 1527, 2004.
- 113) Roehrborn CR, **Kaplan SA**, Abrams P: Tolterodine for the treatment of overactive Bladder symptoms in the male. Society of Female Urology and Urodynamics, Orlando, February, 2005.
- 114) Giuliano F, **Kaplan SA**, Fournie P, Cabanis MJ and Astruc B: Tadalafil shows no clinically significant haemodynamic interaction with alfuzosin. Eur Urol, 4(3): 537, 2005.
- 115) **Kaplan SA**, Roehrborn C, Lee M, The Medical Therapy of Prostatic Symptoms (MTOPS) Research Group: The superior beneficial effect of combination therapy with doxazosin and finasteride versus either drug alone on clinical progression of benign prostatic hyperplasia in the MTOPS trial was not dependent on patients having prostatic enlargement at baseline. Eur Urol, 4(3): 841, 2005.
- 116) Roehrborn CG, **Kaplan SA**, Noble WD, Lucia SM, Slawin KM, McVary KT, Kusek JW, Nyberg LM: The impact of acute or chronic inflammation in baseline biopsy on the risk of clinical progression of BPH: Results from the MTOPS study. J Urol, 173 (4): 1346, 2005.
- 117) McVary KT, Helfand B, Roehrborn CG, Donnell RF, Bruskewitz RC, **Kaplan SA**, Kusek JW, Coombs L, Slawin KM: Variation in IRB review of a multi – center clinical trial study protocol. J Urol 173(4):377, 2005.

- 118) Te AE, Sandhu JS, Reddy B, Ng CK, Gonzalez RR, **Kaplan SA**: The first 200 patients treated with high – power KTP photoselective laser vaporization prostatectomy: The New York Presbyterian experience. J Urol 173(4): 423, 2005.
- 119) Malloy TR, Sandhu JS, Smith AL, Reddy B, Harryhill JF, **Kaplan SA**, Te AE: Photoselective vaporization of the prostate (PVP) in anticoagulated patients: a multicenter retrospective evaluation of feasibility. J Urol 173(4):423, 2005.
- 120) **Kaplan SA**, Roehrborn CG, Lee MW, and the MTOPS Research Group: The superior beneficial effect of combination therapy with doxazosin and finasteride versus either drug alone on clinical progression of benign prostatic hyperplasia is not dependent on patients having prostate enlargement at baseline: data from the medical therapy of prostatic symptoms (MTOPS) trial. J Urol 173 (4): 443, 2005.
- 121) Roehrborn CG, **Kaplan SA**, Lee MW, Slawin KM, McVary KT, Kusek JW, Nyberg Jr LM: Baseline post void residual urine volume as a predictor of urinary outcomes in men with BPH in the MTOPS study. J Urol 173 (4): 443, 2005.
- 122) Slawin KM, McConnell JD, Roehrborn CG, **Kaplan SA**, Smith Jr JA, Lepor H, Diokno AC, Noble WD, Nyberg Jr LM, Kusek JW, Kattan MW: Development of a nomogram to predict acute urinary retention or BPH – related surgery with or without medical therapy in men with BPH based on data from the MTOPS trial. J Urol 173 (4): 444, 2005.
- 123) Roehrborn CG, **Kaplan SA**, Lee MW, Slawin KM, McVary KT, Kusek JW, Nyberg Jr LM: A comparison of men with a four point increase – confirmed or not confirmed - in the AUA symptom score – results from the MTOPS study. J Urol 173 (4): 445, 2005.